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Abstract: 
Faecal calprotectin or lactoferrin can identify post-operative 
recurrence in Crohn’s disease. 
Background: 
Identifying Crohn’s disease recurrence in symptomatic patients after 
ileocaecal resection is difficult as symptoms may reflect the effect of surgery 
rather than active disease. The aim of this study was to evaluate faecal 
concentrations of granulocyte degradation products (faecal calprotectin and 
faecal lactoferrin) in this post-operative setting. 
 
Methods: 
A post-operative cohort of 104 patients (median follow up of 24 months) 
provided a single stool sample. A second cohort of 13 patients was followed 
prospectively for 1 year with regular faecal calprotectin (FC) and faecal 
lactoferrin (FL) measurements. Faecal measurements were compared with 
symptom diaries, the Harvey Bradshaw Index (HBI), endoscopic 
examination, C-reactive protein (CRP) and platelet measurement. 
 
Results: 
Both faecal calprotectin and faecal lactoferrin correlated significantly with 
Harvey Bradshaw Index (r = 0.532, P< 0.001, r = 0.687, P< 0.001 
respectively). Twenty eight patients with severely clinically active disease 
had high mean (s.e) levels of faecal calprotectin (661.1(119.1) µg/g) and 
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faecal lactoferrin (116.6(32.2) µg/g); and forty three patients with clinically 
inactive disease had low levels of faecal calprotectin (70.2(27.1) µg/g) and 
faecal lactoferrin (5.9(2.4) µg/g). In patients with mild to moderately clinically 
active disease, faecal calprotectin and faecal lactoferrin identified individuals 
with and without recurrent inflammatory disease. In the uncomplicated 
course, both markers (faecal calprotectin and lactoferrin) normalized within 
2 months. Faecal markers were more accurate at predicting clinical disease 
activity than C-reactive protein, platelet count or endoscopic appearance. 
 
Conclusion: 
Faecal calprotectin and faecal lactoferrin are non-invasive tests that can 
help to identify disease recurrence in symptomatic post-operative patients 
[1]. 
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1.0 Rationale for research: 
Crohn’s disease is a serious and debilitating chronic disease affecting 
1:1000 of the adult population. Onset of the disease is often in childhood or 
early adulthood. Crohn’s disease is notoriously variable in presentation and 
behaviour. At the severe end of the spectrum there is a substantial 
impairment of the quality of life and studies have suggested 15-20% of 
Crohn’s disease patients will be rendered unable to work by their disease. 
The study of post-operative events in Crohn’s disease represents a unique 
opportunity to identify the disease recurrence in post-operative patients. 
 
As there is no single gold standard test, endoscopy and histology is used for 
detecting and quantifying gastrointestinal inflammation. However this 
method is invasive, expensive and not well tolerated by patients [2]. In the 
search for less-invasive methods for diagnosis and monitoring of 
inflammatory bowel disease, faecal calprotectin and lactoferrin show 
promise as simple, non-invasive, inexpensive sensitive and specific 
parameters to detect gastrointestinal inflammation [3-6]. Other various 
biological and serological markers such as C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), Anti-saccharomyces cerevisiase 
(ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) have low 
sensitivity and specificity for gastrointestinal inflammation and poorly 
correlate with disease activity [3, 7, 8].  
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Smokings, perforating behaviour, ileal or ileocolonic location and female sex 
have all been associated with a tendency to early and aggressive 
recurrence after resectional surgery. Recognition of these factors can 
provide a means to stratify risk broadly within a population, but prediction of 
recurrence in an individual remains poor. After resection surgery patients 
with Crohn’s disease often develop symptoms suggestive of relapse. It is 
hard to establish clinically whether these symptoms are due to recurrence or 
rapid gut transit, as a consequence of adhesions after surgery, salt 
malabsorption or functional bowel disorder. 
 
The ideal assessment of the post-operative patient would be a reliable, non-
invasive marker of recurrent disease that can be monitored, correlating both 
with symptom relapse and mucosal ulceration. Faecal concentration of 
granulocyte degradation products (faecal calprotectin and lactoferrin) may 
therefore offer a suitable method for assessment of disease activity after 
ileocolonic resection. 
 
Previous research has shown both faecal calprotectin and lactoferrin are 
able to differentiate organic from functional disease, simple to use, reliable, 
inexpensive and sensitive for gastrointestinal inflammation and non-
invasive. The clinical usefulness of faecal calprotectin and lactoferrin in the 
post-operative setting has not been prospectively established. 
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Quantitative measurement of faecal calprotectin and faecal lactoferrin may 
offer a valuable method as non- invasive markers in assessing the 
symptomatic post-operative patient in Crohn’s disease. 
To investigate this above hypothesis this study had the following aims: 
1)  To determine whether faecal calprotectin and faecal lactoferrin 
measurements in symptomatic post-operative Crohn’s patient can 
differentiate those with early disease relapse from those with late relapse. 
2) To compare faecal calprotectin and faecal lactoferrin with other 
measurements of inflammatory activity such as C-reactive protein, white cell 
count, platelet count, clinical disease activity index (HBI) and endoscopic 
finding. 
3) To identify the heterogeneous group of patients (those with mild to 
moderate disease activity) using CRP, white cell count and faecal 
calprotectin and lactoferrin and there correlation and also looking at 
smoking status and maintenance therapy with these markers.  
4) To determine how faecal calprotectin and faecal lactoferrin correlate 
with each other after resection. 
5) To determine the immediate post-operative course of faecal 
calprotectin and faecal lactoferrin after ileocaecal resection. 
6) To determine whether these faecal markers could demonstrate 
inflammatory activity and identify post-operative disease recurrence.  
7) To identify if there is a difference in this two markers among 
uncomplicated and complicated group (with post-operative complications 
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like anastomotic leak, intra-abdominal collection, wound infection and 
disease recurrence)   of patients in immediate post-operative setting. 
 
This thesis initially gives all background information about Crohn’s disease 
including post-operative setting and faecal markers (literature review) in 
introduction chapter. Second chapter has details of the experiments used 
for measuring the concentration of CRP, white cell count, platelet count and 
faecal calprotectin and faecal lactoferrin. The results chapter (both cross-
sectional and longitudinal study) addresses the aims of the study. Lastly the 
discussion chapter gives the conclusions of the study along with examining 
the literature critically and future prospects in the use of faecal calprotectin 
and lactoferrin as non-invasive markers in post-operative setting.  
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1.1 Introduction: 
Crohn’s disease is a chronic relapsing disease which affects any part of the 
gastrointestinal tract from mouth to anus, but is most often restricted to 
small bowel, in particular the terminal ileum (figure 1.1). It is characterised 
by patchy transmural inflammation. It can involve perianal skin lesions or 
multiple areas of small bowel with normal bowel (skip lesions) in between or 
may involve the whole of the colon or small bowel extensively. It may be 
defined by location (terminal ileal, ileocolic, colonic, or upper 
gastrointestinal) or by disease pattern (inflammatory, fistulating or 
structuring). The involved bowel may be narrowed, thickened, with deep 
ulcers and fissures in the mucosa: giving a cobble-stone appearance (figure 
1.2).  
 
1.2 History: 
What we call now Crohn’s disease was described in detail by a Glaswegian 
surgeon, Kennedy Dalziel in the British Medical Journal (1913) as chronic 
intestinal enteritis. In the 20th century between 1914 and 1932, lots of 
articles describing chronic intestinal enteritis were written. Finally in 1932 
the definitive paper describing the condition as regional ileitis was published 
and named after first author: Burrill B Crohn, a Mount Sinai Hospital 
physician [9, 10]. 
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1.3 Epidemiology: 
The incidence of Crohn’s disease is 5-10 per 100,000 per year with a 
prevalence of 50-100 per 100,000. It is generally a disease of young people 
with a peak incidence between 10 and 40 years. But it may affect people of 
any age group although 15% of people are over the age of 60 years at 
diagnosis. There are marked differences between ethnic groups with some 
(such as Ashkenazi Jews) having a particularly high incidence [11-14]. 
 
Figure 1.1 - Endoscopic picture of Ileocolic Crohn’s disease. 
 
Figure 1.2 - Crohn’s disease pattern showing narrowing, ulceration, fistulae- 
cobble stone appearance (image from odlarmed.com). 
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1.4 Pathogenesis: 
The aetiology of Crohn’s disease remains unknown. The consensus is that 
Crohn’s disease is a response to environmental triggers like infection, drugs 
or other agents in genetically susceptible individuals. Epidemiological 
studies have considered diet, drug, vaccination history, seasonal variation, 
water and social circumstances for the pathogenetic mechanism of Crohn’s 
disease. The gut/environmental interface includes work on the luminal 
bacteria, epithelial glycocalyx, mucus, epithelial remodelling and barrier 
function, and lastly immune and epithelial interaction. The inflammatory 
factors have been examined through inflammatory mediators, lymphocyte 
trafficking, cell signalling pathways, cytokine profiles, and interaction 
between stromal and immune cells [15].  
 
The genetics approaches included linkage studies, candidate gene studies 
and recently Genome Wide Association Studies (GWAS). More than fifty 
confirmed inflammatory bowel disease genes have now been identified. 
Inflammatory bowel disease is associated with variation in CARD15, IL23, 
IL12B, JAK2 and STAT3, these are associated with inflammatory bowel 
gene susceptibility consistent with newly described role of IL23 signalling 
and Th13 cells in disease pathogenesis [16]. In Crohn’s disease NOD2 and 
autophagy genes ATG16L1 and IRGM are defective in different aspects of 
bacterial handling [17]. Wide genome associated studies have been 
successful in defining the genetic architecture and identifying susceptible 
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genes involved in Crohn’s disease. This will help to explore more in detail 
the natural history of this complex disease in future.  
 
1.4.1 Environmental factors: 
Many environmental factors have been proposed as mentioned above in 
Crohn’s disease susceptibility. These factors include are diet, domestic 
hygiene, other microbial or viral antigens and smoking. 
 
1.4.2 Diet: 
Many studies have proposed that diet may play a role in Crohn’s disease, 
either through infectious agents in food or via immune response to dietary 
antigens. Milk has been implicated to be involved with Crohn’s disease, in 
particular the Mycobacterium avium subspecies paratuberculosis. Although 
Mycobacterium paratuberculosis is a causative agent in Johne’s disease, 
which is a form of inflammatory bowel disease in deer, sheep, cattle and 
monkeys: this theory has not been confirmed [18]. 
 
1.4.3 Domestic Hygiene: 
Better hygiene during childhood may be associated with more risk of 
developing inflammatory bowel disease. This has been proposed to work in 
two ways: either these individuals have less antigen exposure in the form of 
bacteria or virus in turn less immune resistance or immune tolerance 
requires continuous exposure to danger. Secondly, it has been proposed 
that immune tolerance requires continuous exposure to danger. According 
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to these hypotheses inadequate exposure to environmental stimuli in early 
childhood may lead to immune intolerance. This may suggest autoimmunity 
among less exposed or clean individuals in later life [19, 20]. 
 
1.4.4 Microbial or viral antigens including vaccines: 
Bacteria and viruses may trigger inflammatory bowel disease. Absence of 
inflammation in various genetic models of colitis such as animals in germ 
free conditions show a role for intra-luminal bacteria in disease 
pathogenesis [21]. Effective therapies and extensive use of antibiotics are 
used in treatment of Crohn’s disease [22]. Either live or attenuated viral 
vaccines may trigger inflammatory bowel disease [23, 24]. The peptides in 
vaccines may mimic self antigens in the bowel leading to an autoimmune 
response and Crohn’s disease. This relationship of vaccines and infection in 
IBD remains controversial [19]. 
 
1.4.5 Smoking: 
One of the most intriguing environmental factors found to be associated with 
inflammatory bowel disease is smoking, both from its potential relevance to 
disease expression and from clear differences found between its frequency 
in Crohn’s disease and Ulcerative colitis. A strong correlation between 
smoking and inflammatory bowel disease was reported in 1982 by Harries 
et al [25]. In 1990, It was demonstrated that there is an association between 
smoking and the more severe course’s of Crohn’s disease [26]. In this study 
group of 174 Crohn’s disease patients who underwent surgery it was shown 
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that over 10 years smokers have 29% increased risk of having a further 
surgery than non-smokers. Five and ten year recurrence rates were 
significantly higher in smokers (36% & 70%) than in non-smokers (20% & 
41%) [26]. In 1994 a multivariate analysis conducted to examine predictive 
factors for clinical, endoscopic and surgical recurrence after surgery found 
smoking to be an independent factor for all three types of recurrence. The 
six year disease free recurrence after surgery was 27% for smokers, 41% 
for ex-smokers and 60% for non-smokers [27].  
 
Effects of cessation of smoking were described by Cosnes et al on short 
term course shown in figure 1.3 [28]. The risk of flare up in the smoking 
quitters did not differ from that in non-smokers and was less than in 
continuing smokers (p < 0.001). Cosnes et al concluded Crohn’s disease 
patients who stop smoking for more than one year have a benign course 
than if they had never smoked. Lindberg, in a study of 221 patients came to 
the conclusion that in heavy smokers the risk of surgical intervention at five 
years and ten years was higher.  Also in this particular study group he found 
smokers to have an increased risk of perforating complications when 
compared to non-smokers [29].  
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Figure 1.3 - Effect of stopping smoking on the post-operative course of 
Crohn’s disease [28]. 
 
In 1998 a study conducted by Timmer et al found that at forty-eight weeks 
after surgery for Crohn’s disease the relapse rate was 30% in non-smokers 
compared to 53% in smokers.  Ex-smokers had a similar relapse rate (35%) 
to non-smokers [30].  In a study by Yamamoto et al in 1999 demonstrated 
the five and ten year recurrence rate after ileocaecal resection for Crohn’s 
was 35% and 55% for smokers compared to 19% and 36% for non-smokers 
respectively(p=0.007) [31].  In another study done by the same group it was 
found that the recurrence rate for Crohn’s colitis at 5,10,and 15 years was 
25%,46%, and 52% respectively for smokers and 11%,15%, and 18% 
respectively for non-smokers.  Smoking was found to be an independent 
significant predictor for poor outcome after surgery for Crohn’s colitis 
following multivariate analysis [32].   
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Another study done by Ryan et al in 2004 examined the impact of stopping 
smoking on re-operation for Crohn’s disease recurrence after surgery. They 
found that patients who stopped smoking were less likely to have required 
(undergone 1, 2, and 3) re-operations.  This data suggests that patients who 
stop smoking reduce the risk of re-operation for recurrence of Crohn’s 
disease [33]. On the contrary, there were two studies which didn’t find any 
relevant correlation between smoking and the recurrence rate after surgery 
for Crohn’s disease.  Both the studies had a small numbers of patients (40 
patients with CD) and detailed data regarding smoking was not included [34, 
35]. 
 
In conclusion, it appears that smoking has a great impact on increasing the 
risk of recurrence after surgery for Crohn’s disease, especially in heavy 
smokers and women. From the studies published, stopping smoking is 
correlated with a lower recurrence rate compared with smokers. Education 
and encouraging patients to stop smoking is important in the management 
of Crohn’s disease as most patients are unaware of the risks involved with 
smoking on their disease [36-40].  How smoking effects Crohn’s disease is 
still unclear.  Potential factors involved include gut permeability, gut mucosal 
composition, perturbation in eicosanoid production, and immune modulation 
as reported in a few studies [11, 41-44]. Correlation between the faecal 
markers and smoking status has been examined in the cross-sectional 
results chapter of this thesis.  
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1.5 Clinical features of Crohn’s Disease: 
Symptoms of Crohn’s disease are heterogeneous, typically including 
abdominal pain, diarrhoea, and weight loss. Systemic symptoms include 
malaise, anorexia, and fever.  Crohn’s disease patients may also present 
with symptoms of intestinal obstruction due to strictures, fistulae and 
abscesses.  Surgery is not curative in Crohn’s disease patients and the 
management is aimed at minimising the impact of disease.  About 50% of 
the patients diagnosed with Crohn’s disease undergo surgical treatment 
within the first 10 years of the disease.  70-80% will require surgery at some 
point in life [45]. The mortality rate of Crohn’s disease is greatest in the first 
two years after diagnosis and in those with upper gastrointestinal disease 
[46].   
 
1.6 Diagnosis:  
The diagnosis of Crohn’s disease can be challenging as there is no single 
gold standard. Colonscopy and biopsy is approximately 70% effective in 
diagnosing the disease, with further test being less effective. Disease in 
small bowel is particularly difficult to diagnose as a traditional colonscopy 
allows access to only the colon and lower portion of small bowel, 
introduction of capsule endoscopy aids in endoscopic diagnosis. White 
blood cell scan have shown to be effective in detecting the location of active 
disease but this procedure is expensive, time consuming and involves 
radiation. So the diagnosis is reached upon by a combination of clinical 
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evaluation, and diagnostic investigations including endoscopic, histological, 
radiological, and/or biochemical investigations. 
 
1.6.1 History and Examination: 
A detailed history must be obtained including the onset of symptoms, any 
recent travel, intolerance to any food, contact with patients with enteric 
illnesses, family history, past medical history of appendicectomy, medication 
(antibiotics and non-steroidal anti-inflammatory drugs), and smoking.  On 
examination, one must observe the general well being of the patient, 
baseline observations, abdominal tenderness or distension, any palpable 
masses, perianal inspection, oral inspection, and digital rectal examination.  
One must look for extra intestinal manifestations like uveitis, episcleritis, 
arthritis, erythema nodosum and pyoderma gangrenosum as well.   
 
1.6.2 Laboratory Investigations: 
Routine laboratory investigations are C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), and full blood count (FBC).  Stool sample must 
be sent for microbiology assay for clostridium difficile toxin. 
 
1.6.3 Procedures to establish the diagnosis: 
To establish the diagnosis ileocolonoscopy and terminal ileum biopsies are 
used, also they help evaluate the extent and provide microscopic evidence 
of Crohn’s disease throughout the colon. Other investigations to evaluate 
the extent of disease are small bowel follow through, small bowel enema, 
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transabdominal ultrasound, computed tomography-enterolysis and magnetic 
resonance imaging.  In certain patients admitted as emergency with right 
iliac fossa abdominal pain, laparoscopy for diagnosis has identified CD. 
Wireless capsule endoscopy may have a role for small bowel imaging.  
 
1.6.4 Histopathology: 
Microscopic features to look for in diagnosing Crohn’s disease are focal 
(discontinuous) chronic inflammation (lymphocytes and plasma cells), 
patchy chronic inflammation, focal crypt irregularity, and granulomas.  
Transmural inflammation, aggregated inflammatory pattern, transmural 
lymphoid hyperplasia, sub mucosal thickening, fissures, sarcoid granuloma 
(including in lymph nodes), and abnormalities of the enteric nervous system 
are the microscopic features seen in the surgical specimen. 
 
1.7 Management: 
There are guidelines for the management of Crohn’s disease that have 
been published and recommended by British Society of Gastroenterology 
[47]. The following medical and surgical treatments are a summary from 
these guidelines. The treatment of Crohn’s disease depends on the disease 
activity, site of disease (ileal, Ileocolic, colonic, other), and behaviour of 
disease (inflammatory, stricturing, fistulating), response to previous medical 
therapy and side effects of medications. Patient’s involvement should be 
actively encouraged in decision making. 
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1.7.1 Medical management: 
The general principles in the management are to consider the site 
(ileal,ileocolic,colonic), pattern (inflammatory,stricturing,fistulating) and 
activity of the disease before treatment decisions are made in conjunction 
with the patient. An alternative explanation for the symptoms other than 
active disease should be considered (such as bacterial overgrowth, bile salt 
malabsorption, fibrotic stricture) and disease activity confirmed (usually 
CRP) before starting steroids. Patients with Crohn’s disease have many 
investigations over their lifetime and imaging should not be repeated unless 
it will alter management or a surgical decision depends on the result. In mild 
ileocolonic disease high dose mesalazine may be sufficient as initial 
therapy. Patients with moderate to severe or those with mild disease that 
has failed to respond to oral mesalazine, oral prednisolone 40mgs daily is 
appropriate. Prednisolone should be reduced gradually over a period of 8 
weeks. Active ileal or ileocolonic Crohn’s disease should be treated with 
high dose of budesonide, corticosteroids & nutritional therapy. Surgery is 
tailored depending on disease severity and patients view [48-51]. Systemic 
corticosteroids are used in treating severely active localised ileocaecal 
Crohn’s disease [52]. Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 
0.75-1.5 mg/kg/day may be used in active Crohn’s disease as adjunctive 
therapy and as a steroid sparing agent or Patients who relapse, 
azathioprine/mercaptopurine should be added (or, if intolerant, methotrexate 
is considered) [53-55]. In fistulating and perianal disease, the initial 
management aim should be to treat active disease and sepsis, defining the 
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anatomy, supporting nutrition and potential surgery. At times MRI and 
examination under anaesthetic are particularly helpful. Metronidazole 
400mgs three times daily is appropriate first line of treatment for simple 
perianal fistula. If distal obstruction and abscess has been ruled out 
azathioprine or mercaptopurine are effective for enterocutaneous fistulae. 
Infliximab infusions at 0,2 and 6 week is reserved for those patients whose 
perianal or enterocutaneous fistulae are refractory to other treatments and 
used as a part of a strategy that includes immunomodulation and surgery. 
Though surgical options such as seton drainage, fistulectomy and use of 
advancement flaps in combination with medical treatment is appropriate for 
persistent or complex fistulae [56-58]. In maintenance of remission patients 
who smoke should be offered help to stop and immunomodulation with 
azathioprine, mercaptopurine or methotrexate is usually appropriate as 
steroids are withdrawn. 
 
1.7.2 Surgical management: 
Surgery should be advised for Crohn’s disease not responding to intense 
medical therapy. The decision to operate is best taken by the 
gastroenterologist and colorectal surgeon in conjunction with the patient. 
Surgery for Crohn’s disease is undertaken for symptomatic rather than 
asymptomatic, radiological disease because the disease is pan-enteric and 
usually recurs following surgery. The general principles are preoperative 
counselling and marking of stoma sites. The procedure of choice in acute 
fulminant Crohn’s disease is subtotal colectomy leaving a long rectal stump, 
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either incorporated into the lower end of the abdominal wound or mucous 
fistula. Resection should be limited to macroscopic disease. Primary 
anastomosis should not be performed in presence of malnutrition or sepsis. 
Crohn’s disease has two different forms, a perforating (acute free 
perforation, subacute perforation with abscess formation and intestinal 
fistula formation) and non-perforating (intestinal obstruction, haemorrhage, 
medical intractability and toxic dilation) [59].Localised ileocaecal Crohn’s 
disease with obstructive symptoms can be treated with primary surgery [60]. 
Abdominal abscesses are managed with antibiotics and percutaneous or 
surgical drainage followed by delayed resection if necessary [61]. 
Stricturoplasty is performed when the length of small bowel stricture is <10 
cm but is not recommended for colonic Crohn’s disease. Endoscopic 
dilatation of the strictures is preferred for the management of accessible 
short strictures [62, 63].  
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1.8 Literature review- 
Bibilographical searches were performed in MEDLINE electronic database 
up to September 2009 looking for the following keywords words (all fields): 
inflammatory bowel disease or Crohn’s disease or Ulcerative Colitis, 
postoperative Crohn’s disease or surgery for Crohn’s disease, faecal 
markers, faecal calprotectin or faecal lactoferrin, clinical indices. Further 
articles were identified by use of the related-articles function in PubMed. A 
manual citation search of references given in the retrieved articles on the 
subject was also performed. Only articles published in English language 
were chosen.    
 
1.8.1 Postoperative Crohn’s disease- Background: 
Crohn’s disease is a chronic inflammatory bowel disease with complex 
pathophysiology. Its heterogeneous clinical presentation has challenged 
clinicians due to its inconsistency in patient presentation, leading to 
difficulties in predicting the clinical course [64]. Over three quarters of 
patients diagnosed with Crohn’s disease require surgery and about one 
third of these patients will require further surgery when followed long term 
[65].Despite recent progress in medical therapy, surgery is still necessary 
for the complications of Crohn’s disease and bowel resection and has 
resulted in better outcomes for many patients. However multiple operations 
can risk short bowel syndrome and result in difficult procedures due to 
adhesions [66].  
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Numerous pathological and demographical factors have been investigated 
for their supposed influence on recurrence of Crohn’s disease [67]. The only 
assessed environmental risk factor  seems to be smoking to identify 
recurrence after surgery, as described in detail in earlier section 
[38].Several factors like gender, family history of Crohn’s disease, presence 
of granulomas, obstructing, fistulising nature of disease, length of surgical 
margins, site and number of sites involved, type of operation and number of 
anastomosis did not show any definite factor to be implicated in recurrence 
[68-70]. A number of studies have revealed several risk factors for post 
operative recurrence; however the results are not similar because of 
incompatible patient populations and clinical manifestations [67, 71, 72]. 
Despite these studies post-operative recurrence remains clinically 
important, but poorly understood. 
 
1.8.2 Indications for surgery: 
Two large studies found the cumulative probability of surgery of 78% at 20 
years from the diagnosis of Crohn’s disease. In these studies 66% of 
patients had limited small bowel Crohn’s disease requiring surgery 
compared to 58% for colonic Crohn’s disease [73, 74]. The most common 
reason for surgery has traditionally been for complications of Crohn’s 
disease like intestinal obstruction, strictures and perforation (22% to 45%) or 
medical intractability (16% to 68%) [66, 73, 75].  
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1.8.3 Recurrence after surgery: 
Recurrence after surgery is usually at the anastomotic site after long term 
follow up of Crohn’s disease [76]. Only 20% of patients develop clinical 
symptoms compared to endoscopic recurrence of 73% after surgery at 1 
year follow up and at 3 years 34% and 85% (respectively) [77]. This study 
demonstrated that the development of one form of recurrence correlates 
poorly with other. Two large studies have shown that primary ileocolic 
surgery for ileocolic disease is generally associated with an increased 
reoperation rate compared to isolated ileal or colonic disease [73, 74]. 
These studies showed 53% (ileocolic disease), 45% (colonic disease) and 
44% (ileal disease) reoperation rate after follow up of thirteen years. A few 
small studies have shown no difference in reoperation rate [78, 79]. Most of 
the studies consistently conclude that about 50% of patients who have 
undergone ileocolic resection for Crohn’s disease will require further 
operation within 10 years [75, 80]. 
 
Some studies have identified that more extensive disease preoperatively is 
associated with increased risk of recurrence for both symptoms [68, 81, 82] 
and reoperation rate [83]. A few studies have suggested that patients with 
Crohn’s disease who present with bowel perforation are more likely to have 
reoperation [70, 84, 85] on the contrary another study [86] suggested that 
perforating nature of disease does not carry a greater risk of recurrence. 
Stenosing and fistulising Crohn’s disease patients of ileocaecal site have no 
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difference in recurrence rate after bowel resection after 9 year follow up 
[87].     
 
Bowel sparing surgical policy, which involved resecting only the 
macroscopic diseased bowel [88, 89], was found to have reasonable 
recurrence rates compared to extensive bowel resection or presence of 
microscopic disease at surgical margins [90]. Stricturoplasty for Crohn’s 
disease patients for small bowel stricture<10 cm has shown to have a 
similar postoperative recurrence rate to resection [63, 91, 92].    
 
Further clinical studies based on specific anastomotic techniques have had 
variable results. Stapling techniques results have been shown to have 
increased recurrence after resection as a result of localised ischaemic injury 
[82, 93]. Other studies have shown no difference between hand sewn or 
stapled anastomosis [94, 95]. No randomised trials exist and due to different 
sites of disease, follow up time, and specific techniques, so it is not easy to 
make a firm conclusion. Clinical, endoscopic and histological criteria are all 
used in post-operative setting but their correlation is imperfect [73, 96-98] 
and the standard clinical assessment tools for measuring CD activity are not 
necessarily useful in post-operative setting [97]. 
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1.8.4 Post-operative complications: 
2% of Crohn’s disease patients develop post-operative complications in the 
form of leaks or dehiscence even with bowel sparing surgery or 
stricturoplasties. These complications are associated with pre-existing 
impaired nutritional state, steroid therapy, existing sepsis or obstruction and 
multiple previous surgeries. Two studies [99, 100] have shown that 
development of post-operative complications is associated with increased 
recurrence rate and another study [101] has shown no relationship between 
increased recurrence with post-operative complications. 
 
1.8.5 Medical prophylaxis against post-operative recurrence: 
The effect of 5-aminosalicylate in recurrence post-operatively in Crohn’s 
disease is controversial. If there is a beneficial effect it is likely to be small 
[102, 103]. Two randomised control studies [104, 105] have reported that 
nitroimidazole antibiotics are effective but dosage and duration remain 
questionable. The use of immunosuppressant agents like azathioprine, 6-
mercaptopurine and antitumor necrosis (TNF) alpha antibody therapy have 
been shown to produce mucosal healing in the treatment of post-operative 
disease recurrence [106, 107]. Conversely, these immunosuppressants do 
have side-effects and are therefore only desirable for targeted therapies 
with proven gut inflammation. Steroid therapy use in post-operative setting 
is not recommended for prophylaxis [50, 108]. Rutgeerts et al proposed an 
algorithm for the prophylaxis of Crohn’s disease post-operatively as shown 
in figure 1.4. 
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Resection of all macroscopic disease
Low and intermediate risk
• fibrostenotic disease
•No smoking
•First operation
High risk
•Ileocolonic anastomosis
• smoking females
•Perforating disease
•Repeated surgery
No therapy
Ileocolonoscopy or small bowel x-ray
Six months after surgery
Azathioprine 2.5 mg/day 
Or 6 mercaptopurine 1.5mg/kg/day
Six monthly follow up
(2 monthly blood count)
No recurrence
Mild lesions
Severe lesions
Limited extent
Severe lesions
Extent important
Yearly
follow up
5- ASA 4gms/day (?)
Yearly follow up
No therapy
Figure 1.4 - Algorithm for prophylaxis of Crohn’s recurrence after resection 
(Rutgeerts et al) [109]. 
 
1.9 Faecal Markers: 
There is no gold standard test used in detecting and quantifying 
gastrointestinal inflammation. In about 70% of Crohn’s disease patients, 
endoscopy and histology has been used to detect and quantify 
gastrointestinal inflammation. However this method is invasive, expensive, 
not well tolerated by patients and not examine small bowel completely [2]. In 
the search for less-invasive methods for diagnosis and monitoring of 
inflammatory bowel disease, faecal calprotectin and lactoferrin show 
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promise as simple, non-invasive, inexpensive sensitive and specific 
parameters to detect gastrointestinal inflammation [3-6]. Other various 
biological and serological markers such as C-reactive protein (CRP), 
erythrocyte sedimentation rate (ESR), Anti-saccharomyces cerevisiase 
(ASCA), anti-neutrophil cytoplasmic antibodies (ANCA), immunoglobulins 
IgA, Alpha-1-antitrypsin, Alpha-2-macroglobulin, faecal lysozyme, faecal 
myleperoxidase, faecal elastase, faecal lactate and whole gut lavage have 
low sensitivity and specificity for gastrointestinal inflammation and poorly 
correlate with disease activity [3, 7, 8, 110]. Although various markers have 
been investigated, none has been shown to be ideal or superior to our 
current diagnostic tools. Nevertheless, CRP is a useful marker and should 
be preferred in crohn’s disease as it correlates well with disease activity in 
some studies but again have low sensitivity and specificity.  
In conclusion, assessment of disease activity in patients with IBD is 
important both in clinical practice and in trials. The data is limited or 
inconsistent, however our knowledge of the inflammatory network involved 
in inflammatory bowel disease grows, and this may give rise to more 
sensitive and specific markers. As the main pathophysiological event in 
inflammatory bowel disease is neutrophils influx into the mucosa, 
neutrophils derived markers; especially faecal calprotectin and faecal 
lactoferrin show the most promising markers to assess disease activity in 
gastrointestinal inflammation. 
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1.9.1 Faecal Calprotectin: 
Calprotectin was first described in 1980 by Fagerhol et al. It is a 36 kDA 
calcium and zinc binding protein and constitutes 60% of total soluble cytosol 
proteins in human neutrophil granulocytes. After granulocytes are released 
from bone marrow and reach gastrointestinal tract, they release 
antimicrobial substances which include calprotectin [111]. Hence 
calprotectin in faeces is directly proportional to leucocytes relocation to the 
gastrointestinal tract. A five day faecal excretion of leucocytes measured 
with Indium-111 has shown close correlation with faecal calprotectin in 
quantification of intestinal inflammation [112-115]. It is expensive, time 
consuming and exposes patient to radiation. Calprotectin has an 
antimicrobial function; it inhibits metalloproteinases and induces apoptosis 
in cell cultures [116, 117]. Once released from granulocytes its 
concentration increases over a hundred times the normal level in blood and 
faeces in rheumatoid arthritis and gastrointestinal inflammation [118-120]. It 
is stable for seven days at room temperature, which means that the faecal 
samples can be posted to a laboratory or brought directly to clinic. Five 
grams of faeces is enough to establish the presence of calprotectin using 
ELISA. Studies done in laboratories across England and in Norway have 
shown the normal level of faecal calprotectin in healthy individuals to be 
50µg/g [2, 110, 118, 121, 122]. Individuals on non-steroidal anti-
inflammatory medications which are associated with enteropathy have 
higher levels of faecal calprotectin. Also differences in diet and levels of 
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physical activity are associated with increased levels of faecal calprotectin 
[123-126] . 
 
1.9.2 Faecal calprotectin as a marker for the diagnosis of inflammatory 
bowel disease: 
The studies shown in the table 1.1 have examined the value of faecal 
calprotectin in diagnosis of inflammatory bowel disease in patients with 
symptoms suggestive of inflammatory bowel disease (both Ulcerative Colitis 
and Crohn’s disease). The mean specificity and sensitivity for diagnosing 
inflammatory bowel disease is 76% (95% CI, 72-79%) and 80% (95% CI, 
77-82%) respectively. Using faecal calprotectin as a marker for diagnosis, 
when compared between Crohn’s disease and Ulcerative Colitis in above 
studies, a higher accuracy was seen in Crohn’s disease (specificity 85% & 
sensitivity 83% in Crohn’s disease, specificity 74% & sensitivity 72% in 
Ulcerative Colitis) [112, 127-138]. 
 
Using faecal calprotectin as a faecal biomarker against histological 
diagnosis of Inflammatory Bowel Disease a meta-analysis [139] of 
prospective studies was performed including healthy patients, patients with 
Crohn’s disease, Ulcerative Colitis, and patients with Irritable Bowel 
Syndrome.  Patients with Inflammatory Bowel Disease showed higher levels 
of faecal calprotectin (219.2 microgram/gram) compared to normal patients.  
Higher levels of faecal calprotectin were shown in Crohn’s disease by 
56microgram/gram when compared with Ulcerative Colitis [112, 127, 129, 
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133, 134, 140, 141].This test of faecal calprotectin didn’t distinguish 
between Crohn’s disease and Ulcerative Colitis clinically as the range of 
values used was very large.   
 
A few studies conducted showed no significant difference in the levels of 
faecal calprotectin in distinguishing between Inflammatory Bowel Disease 
and Colorectal Cancer.  The reason for this is that calprotectin is found 
elevated in many organic processes in the gastrointestinal tract such as 
Colorectal Cancer and gastrointestinal infections.  In this situation where 
faecal calprotectin is elevated colonoscopy as follow up is required to rule 
out causes other than inflammatory bowel disease [139, 142].  In 
conclusion, studies have shown faecal calprotectin to be a better diagnostic 
faecal marker for inflammatory bowel disease than other markers such as 
C-reactive protein, erythrocyte sedimentation rate, ASCA and ANCA [112, 
131, 139]. 
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Table 1.1 - Diagnostic precision of faecal calprotectin for inflammatory 
bowel disease [131]. 
Study Age Patient & 
Disease 
Cut-off level 
Microgram/gram 
Sensitivity (%) Specificity 
(%) 
Carrocio et al 
[127] 
Adults 10 CD 50 100 80 
Carrocio et al 
[127] 
Children 8 CD 50 100 96 
Canani 
et al [128] 
Children 17 CD 
10 UC 
100 93 89 
Bunn et al [134] Children 21 CD 
16 UC 
50 65 100 
Bremner et al 
[133] 
Children 43 IBD 50 95 72 
D’Inca  
et al [130] 
Adults 31 CD 
46 UC 
80 79 74 
Thjodleifsson et 
al [136] 
Adults 49 CD 50 88 91 
Tibble et al [112] Adults 116 CD 50 98 96 
Fagerberg  
et al [140] 
Children 22 IBD 50 95 93 
Schroder  
et al [137] 
Adults 25 CD 
20 UC 
15 93 100 
Silberer et al 
[138] 
Adults 39 IBD 18.6 61 - 
Tibble et al [3] Adults 31 CD 150 100 97 
Limburg et al 
[132] 
Adults 29 IBD 100 94 83 
Kaiser et al [135] Adults 32 CD 
27 UC 
50 63 86 
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1.9.3 Faecal calprotectin in the diagnosis of organic (small or large) 
gastrointestinal disease from functional disorder (IBS) in symptomatic 
patients: 
Clinical symptoms of organic small or large intestinal (IBD or neoplastic 
disease) and functional disorder (IBS) range vary widely, so making specific 
diagnosis from symptoms alone difficult in symptomatic patients. 
Colonoscopy and biopsy is needed for accurate diagnosis. It is expensive, 
uncomfortable and needs general anaesthesia in paediatric patients. Using 
faecal calprotectin, studies have distinguished organic from functional 
gastrointestinal disease [112, 119, 127-129, 131] . These studies showed 
mean sensitivities of 83% (95% CI, 81-84%) and specificities of 84% (95% 
CI, 82-85%). In these studies, apart from faecal calprotectin, CRP and ESR 
were used for diagnostic accuracy of organic and functional disease [143-
145]. Faecal calprotectin showed higher diagnostic accuracy than other two 
markers separately and in combination. In detection of colorectal cancer, 
faecal calprotectin was more sensitive than faecal occult blood [141]. In 
conclusion, from these studies faecal calprotectin could be used to 
distinguish between organic gastrointestinal (coeliac, diverticular, IBD and 
neoplastic  diseases) from functional disease (IBS) in symptomatic patients 
and avoid unnecessary colonoscopies in the latter group [146].  
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1.9.4 Faecal calprotectin as a marker of disease activity and relapse in 
inflammatory bowel disease: 
Several studies have been conducted comparing faecal calprotectin levels 
and disease activity based on clinical disease activity index, histological and 
endoscopic findings [112, 118, 119, 129, 134, 138, 147-152]. These studies 
found faecal calprotectin correlates more closely with histological findings 
than endoscopic appearance in evaluating inflammatory bowel disease 
activity [119]. The histological severity grades of colorectal inflammation 
were predicted with higher levels of faecal calprotectin [132]. Further studies 
looking at the disease extent were performed and these studies did not 
demonstrate the difference in levels of faecal calprotectin and disease 
extent of inflammation apart from disease activity [112, 129, 142]. Levels 
above 50 microgram/gram were better correlated with colitis disease activity 
index than Crohn’s disease activity index (CDAI) [129, 130]. This might be 
due to Crohn’s disease activity index being not sensitive enough to detect 
subclinical inflammation. In conclusion, further studies are needed to 
establish correlation between faecal calprotectin and disease activity index. 
A prospective study performed by Casellas et al demonstrated faecal 
calprotectin levels remained unchanged in clinically inactive Ulcerative 
Colitis and higher levels were seen in patient who relapsed when followed 
up for twelve months [152] .  
Inflammatory bowel disease activity is unpredictable in its course of relapse 
and remission. Faecal calprotectin may have a role in predicting 
inflammatory bowel disease relapse. Higher levels of faecal calprotectin are 
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associated with increased rate of relapse. Study from from Tibble et al 
demonstrated that 90% of patients having high faecal calprotectin at the 
beginning of the study had relapsed within a year and only 10% of them had 
low levels of faecal calprotectin. Thus study concluded faecal calprotectin’s 
sensitivity of 90% and specificity of 83% in predicting relapse [153]. Other 
serological markers like CRP and ESR did not demonstrate any usefulness 
in predicting relapse in patients who were in clinical remission. The 
difference in these markers could be explained that faecal calprotectin 
seems to be a direct marker of inflammatory activity while CRP and ESR 
estimate inflammation indirectly. Another study by Costa et al showed 
similar specificity (89%) and sensitivity (82%) in predicting relapse in 
patients with Ulcerative Colitis but lower specificity (43%) in patients with 
Crohn’s disease. This study used a lower cut off (150microgram/gram 
equivalent to 30mg/litre) and different ELISA assay [154]. Also two other 
studies by Scarpa et al done on Crohn’s disease, predicting relapse using 
faecal calprotectin levels did not show similar outcomes to Ulcerative Colitis. 
This difference could be due to different patterns of gastrointestinal 
inflammation in both diseases [155, 156]. In conclusion, more studies are 
needed on identifying this above difference between Crohn’s disease and 
Ulcerative Colitis, and predicting relapse risk using faecal calprotectin.   
 
 
 
          Chapter 1 - Introduction 
50 
 
1.9.5 Faecal calprotectin in the assessment of inflammatory bowel 
disease treatment response and after bowel resection surgery:  
Only a few studies have been performed using faecal calprotectin as a 
biomarker in the assessment of disease activity clinically, endoscopically 
and histological improvement after treatment. These studies found the 
levels of faecal calprotectin decreased with treatment and correlated with 
clinical, endoscopic and histological progress in a single patient with 
Ulcerative Colitis over 18 week period [150]. Few others demonstrated a 
brief decrease in concentration with infliximab [157]. Follow up of fifteen 
patients on glucocorticoid therapy as treatment of active disease showed 
decrease in faecal calprotectin levels with clinical improvement but did not 
fall into the normal range, suggesting subclinical inflammation in clinically 
inactive disease. Discontinuation of treatment showed immediate increase 
in levels of faecal calprotectin [151]. This is in agreement with other studies 
showing that although patients with IBD achieved clinical remission with 
steroid therapy, microscopic remission is rarely achieved and persistent 
inflammatory changes were found in bowel in majority of patients. 
 
Two studies have been performed so far to assess disease activity using 
faecal calprotectin on patients with Crohn’s disease after bowel resection 
surgery. Orlando et al in 2006 consecutively followed 50 patients who had 
undergone previous resection for Crohn’s disease had showed good 
correlation between faecal calprotectin of >200 mg can be an indication for 
colonoscopy and better sensitivity than ultrasound after 3 months of 
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resection surgery [158]. This study showed good correlation with 
endoscopic disease activity when faecal calprotectin levels were >200 mg 
but low sensitivity (75%) of faecal calprotectin and small sample size of 39 
patients. Costa et al in 2003 showed that after bowel resection only patients 
with post-operative disease recurrence at the anastomotic site had 
increased levels of faecal calprotectin compared to normal levels in patients 
without disease recurrence [129]. In contrast, a study from Costa et al in 
2007 showed increased levels of faecal calprotectin even after ileocolonic 
resection when followed up for long term [155]. This second study explained 
that even with good health, gastrointestinal inflammation persists and 
ileocolonic resection does not heal Crohn’s disease. In summary, further 
prospective studies using faecal calprotectin as a biomarker are needed to 
identify its utility in assessment of inflammatory bowel disease medical 
treatment response and disease recurrence after bowel resection. 
 
1.9.6 Faecal lactoferrin: 
Faecal lactoferrin is a (76kDa) iron binding glycoprotein present in many 
body fluids such as human breast milk, synovial fluid, tears and in 
polymorphonuclear neutrophils. This protein is a major component of 
secondary granules in polymorphonuclear neutrophils and is secreted by 
mucous membranes [159]. This protein plays an important role in the 
defence mechanism (bacteriocidal properties of faecal lactoferrin) of 
mucous membranes during the inflammatory process as polymorphonuclear 
neutrophils degranulate during this process. Faecal lactoferrin concentration 
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in faeces is proportional to the influx of neutrophils translocation to the 
gastrointestinal tract on activation of polymorphonuclear neutrophils [160-
162]. Faecal lactoferrin is stable at room temperature for a long period of 
time (seven days) and is suitable for reflecting inflammatory bowel disease 
activity. Like faecal calprotectin the quantity of faecal lactoferrin can be 
measured with simple enzyme linked immunosorbent assay (ELISA). Since 
faecal lactoferrin is stable at room temperature for seven days the samples 
can be posted to the laboratory or brought to the clinic [2, 138, 163, 164]. 
The normal level of faecal lactoferrin in healthy individuals measured by 
commercially available quantitative ELISA is less than 7.25 
microgram/gram. Individuals currently on non-steroidal anti-inflammatory 
medications that are associated with enteropathy have higher levels of 
faecal lactoferrin [110, 122, 165].  
 
1.9.7 Faecal lactoferrin as a marker for the diagnosis of inflammatory 
bowel disease:  
Studies shown in the table 2.1 have demonstrated the diagnostic accuracy 
of faecal lactoferrin in diagnosis of inflammatory bowel disease in patients 
with clinical history of inflammatory bowel disease (both Ulcerative Colitis 
and Crohn’s disease) [5, 6, 137, 163, 164, 166-172]. The mean specificity 
and sensitivity in diagnosing inflammatory bowel disease is 82% (95% CI, 
79-84%) and 80% (95% CI, 78-83%) respectively. Using faecal lactoferrin 
as a marker for diagnosis, when compared between Crohn’s disease and 
Ulcerative Colitis both had comparable specificity and sensitivity (77% 
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specificity & sensitivity 75% in Crohn’s disease and in Ulcerative Colitis 
specificity of 74% & sensitivity 82%) [173]. When compared between faecal 
proteins like lysozyme, myeloperoxidase, faecal calprotectin and lactoferrin 
in the identification of gastrointestinal inflammation, until now information 
available is spare. Higher levels of faecal lactoferrin were shown in 
Ulcerative Colitis when compared with Crohn’s disease possibly due to the 
short transit time of released neutrophils derived proteins [6, 148].The 
difference in levels of faecal lactoferrin between Ulcerative Colitis and 
Crohn’s disease in these studies was suggested due to the heterogeneous 
nature of Crohn’s disease and they were unable to adequately clarify to 
what degree the amount of ileal versus colonic disease was present in study 
patient. Studies have shown faecal lactoferrin to be a better diagnostic 
faecal marker for inflammatory bowel disease than other markers like C-
reactive protein, erythrocyte sedimentation rate, ASCA, ANCA [144, 174, 
175]. 
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Table 2.1 - Diagnostic accuracy of faecal lactoferrin for diagnosis of 
Inflammatory Bowel Disease [173] . 
Study Control Group Patient & Disease Sensitivity 
(%) 
Specificity 
(%) 
Fine et al 
[169] 
Different colonic diseases 103 IBD 90 98 
D’Inca et al 
[130]  
Different colonic diseases 77 IBD 76 67 
Dai et al [171] IBS and different colonic 
diseases 
13 CD 
42 UC 
92 
90 
80 
88 
Hirata et al 
[170] 
Different colonic diseases 40 CD 
62 UC 
63 
47 
- 
Schroder et al 
[137] 
IBS 45 IBD 82 100 
Kane et al [5] IBS 215 IBD 78 90 
Saitoh et al 
[176] 
Different colonic diseases 13 CD 
18 UC 
54 
67 
- 
Walker et al 
[168] 
IBS 106 IBD 87 68 
Otten et al 
[177] 
IBS 23 IBD 
23 IBD 
78 
78 
90 
99 
Langhorst et 
al [144] 
IBS 43 CD 
43 UC 
82 
90 
60 
67 
Schoepfer et 
al [167] 
IBS 
Other forms of colitis 
36 IBD 
36 IBD 
86 
100 
100 
14 
Schoepfer et 
al [174] 
IBS 
IBS 
36 CD 
28 UC 
83 
91 
96 
96 
CD: Crohn’s disease, UC: Ulcerative Colitis, IBS: irritable bowel syndrome. 
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1.9.8 Faecal lactoferrin in the diagnosis of organic (small or large) 
gastrointestinal disease from functional disorder (IBS) in symptomatic 
patients: 
Similar to faecal calprotectin studies performed, faecal lactoferrin has 
distinguished organic (IBD or neoplastic disease) from functional (IBS) 
gastrointestinal disorders [112, 130, 178]. In contrast to faecal calprotectin, 
a study concluded in the detection of colorectal diseases (IBD, colorectal 
cancers and polyps), faecal lactoferrin and faecal occult blood tests were 
equally useful but cannot replace each other as screening tests [163, 179]. 
Faecal lactoferrin (as a marker of neutrophilic intestinal inflammation) could 
be used to distinguish between organic gastrointestinal diseases from 
functional disease in symptomatic patients and avoid unnecessary 
colonoscopies in the latter group [178]. 
  
1.9.9 Faecal lactoferrin as a marker of disease activity and relapse in 
inflammatory bowel disease: 
Several studies have been conducted between faecal lactoferrin levels and 
disease activity based on clinical disease activity index, histological and 
endoscopic findings. These studies found faecal lactoferrin correlates 
closely with histological lesions in evaluating inflammatory bowel disease 
activity [6, 167, 168, 176, 180]. Faecal lactoferrin correlates significantly with 
histological lesions in Crohn’s disease in contrast to faecal calprotectin. In 
Ulcerative Colitis and ileocolonic and colonic Crohn’s disease faecal 
lactoferrin correlates significantly with endoscopic score [130, 172, 181]. A 
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study from Sipponen et al in 2008 on Crohn’s disease demonstrated that in 
active disease increased levels of both faecal lactoferrin and faecal 
calprotectin were significantly higher in colonic than in ileal disease. Faecal 
lactoferrin, but not faecal calprotectin was significantly higher also in 
ileocolonic than in ileal disease. In strictly ileal disease, faecal lactoferrin 
correlated with endoscopic severity but not faecal calprotectin [172]. In 
another study close correlation between faecal lactoferrin levels and 
endoscopic and histological findings in patients diagnosed with Ulcerative 
Colitis was demonstrated. In patients with Crohn’s disease this study only 
demonstrated correlation between faecal lactoferrin levels and histological 
findings but not with endoscopic appearances [130] . A study based on 
clinical disease activity in IBD has shown increased levels of faecal 
lactoferrin with a higher grade of disease activity. In the assessment of 
disease activity in inflammatory bowel disease both faecal lactoferrin and 
calprotectin are equally useful [155, 165].  
 
Faecal lactoferrin was shown to predict inflammatory bowel disease relapse. 
Higher levels of faecal calprotectin are associated with increased rate of 
relapse. A study proved faecal lactoferrin’s sensitivity is 62% and specificity 
is 65% in predicting relapse but when considering relapse in first three 
months a better sensitivity of 100% was obtained [182]. Another study in 
paediatric IBD patients showed higher levels of faecal lactoferrin in patients 
who relapsed clinically and normal levels in patients who were in clinical 
remission. This study also concluded that persistent higher faecal lactoferrin 
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levels may predict early relapse in patients tapering off steroid therapy 
[168]. In conclusion, more studies are needed in predicting relapse risk after 
bowel resection surgery, and order of relapse using faecal lactoferrin.   
 
1.9.10 Faecal lactoferrin in the assessment of inflammatory bowel 
disease treatment response and after bowel resection surgery:  
Only two studies have been performed using faecal lactoferrin as a 
biomarker in the assessment of disease activity clinically, endoscopically 
and histological improvement after medical treatment. These studies found 
levels of faecal lactoferrin decreased rapidly after first infusion of infliximab 
and also in all patients who responded clinically after the first infusion [183, 
184].  
Two studies have been performed so far to assess disease activity using 
faecal lactoferrin on patients with Crohn’s disease after bowel resection 
surgery [155, 185]. Firstly, Scarpa et al showed that faecal lactoferrin levels 
stayed high after surgery even in patients who were in remission. They also 
observed that faecal lactoferrin levels were significantly increased in 
patients who had clinical recurrence. Secondly, a study from Parsi et al 
done on IBD patients with an ileoanal pouch showed faecal lactoferrin levels 
to be high in pouchitis with normal levels in symptoms from irritable pouch 
syndrome. This study also concluded that faecal lactoferrin as a initial 
diagnostic test in symptomatic pouch patients to be cost effective when 
compared with metronidazole therapy alone and pouch endoscopy with 
biopsy.  
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1.10 Aims of study: 
Previous research has shown both faecal calprotectin and lactoferrin are 
able to differentiate organic from functional disease, simple to use, reliable, 
inexpensive and sensitive for gastrointestinal inflammation and non-
invasive. The clinical usefulness of faecal calprotectin and lactoferrin in the 
post-operative setting has not been prospectively established. 
 
Quantitative measurement of faecal calprotectin and faecal lactoferrin may 
offer a valuable method as non-invasive markers in assessing the 
symptomatic post-operative patient in Crohn’s disease. 
To investigate this above hypothesis this study had the following aims: 
1) To determine whether faecal calprotectin and faecal lactoferrin 
measurements in symptomatic post-operative Crohn’s patient 
can differentiate those with early disease relapse from those 
with late relapse. 
2) To compare faecal calprotectin and faecal lactoferrin with 
other measurements of inflammatory activity such as C-
reactive protein, white cell count, platelet count, clinical 
disease activity index (HBI) and endoscopic finding. 
3) To identify the heterogeneous group of patients (those with 
mild to moderate disease activity) using CRP, white cell count 
and faecal calprotectin and lactoferrin and there correlation 
and also looking at smoking status and maintenance therapy 
with these markers.  
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4) To determine how faecal calprotectin and faecal lactoferrin 
correlate with each other after resection. 
5) To determine the immediate post-operative course of faecal 
calprotectin and faecal lactoferrin after ileocaecal resection. 
6) To determine whether these faecal markers could 
demonstrate inflammatory activity and identify post-operative 
disease recurrence.  
7) To identify if there is a difference in this two markers among 
uncomplicated and complicated group (with post-operative 
complications like anastomotic leak, intra-abdominal 
collection, wound infection and disease recurrence)   of 
patients in immediate post-operative setting. 
 
This study involved investigation of two related arms: cross sectional and 
longitudinal studies. The Cross sectional study addresses the first four aims 
of the study and findings are shown in chapter-3 of this thesis. The 
longitudinal study addresses the last three aims of the study and findings 
are shown in chapter-4 of this thesis. This study was designed to be 
achievable in the time frame and within the budget available as well as 
acceptable to patients by virtue of not involving any invasive tests.  
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2.1 Brief Overview:  
In this section I have outlined my personal contributions to the study and the 
areas where I have been helped by others to complete this project. I began 
my work by writing a rough study design protocol and presented it to my 
supervisor in November 2005.  After discussing it with my supervisor we 
came to an agreement for a final study. Subsequently I started to apply for 
funds for the project.  I will discuss the study design details later in this 
section of the thesis. I applied to a surgical research fellowship at Royal 
College of Surgeons, London. I was shortlisted for funding there but did not 
get it. Through my supervisor I got introduced to (IBD-SCAN®; Techlab, 
Blacksburg, Virginia, USA) ScheBo Biotech Company (Basingstoke, UK 
supplier). I discussed my project with the director of ScheBo Company. I got 
approved for free faecal lactoferrin kits for the project. The remaining 
funding was provided by my supervisor Dr. J.C. Mansfield’s’ research funds. 
I was employed as a research fellow at Newcastle upon Tyne Hospitals 
NHS Trust who covered the rest of the funding for my on-call clinical 
commitments. I was employed fulltime as clinical research fellow with on-
call commitments from October 2005 until December 2007. 
 
I applied to the Research and Development department at Newcastle upon 
Tyne NHS Trust to act as a sponsor for this project under the department of 
health guidelines for research in health and social care and got approval 
from them. Next I applied to Gateshead and South Tyneside Ethics 
Committee (Reference No. 06/Q0901/4). I was called for an interview along 
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with my supervisor by the Ethics Committee. The project was explained to 
them. I was advised by them to make a few corrections on my application 
form (patient information leaflets and consent forms). After doing that the 
committee accepted my application and granted ethical approval for this 
study in March 2006. 
 
I began by attending IBD clinics in Newcastle to recruit patients. I 
approached patients who had ileocaecal resection for Crohn’s disease (for 
cross-sectional study) and also patients who were planned for undergoing 
ileocaecal resection (for longitudinal study). I explained the project to the 
patients.  Once they agreed to participate in the project I would take consent 
and obtain clinical data from them. I would explain to them that they need to 
give a faecal sample. For this they would be provided a faecal sample 
collection kit (figure 2.1) and postal kit (figure 2.1a) which they take home. 
They get a faecal sample at home and post it to the laboratory. For patients 
who did not have facility to post the faecal sample I made arrangements to 
personally go to their home and pick up the samples.  
 
The faecal sample kit consisted of a faecal collection bag, test tube with 
spatula, test tube holder, cardboard box, and self addressed stamped 
envelope.  During the interview I explained to the patient how to collect a 
faecal sample in the faecal bag.  The patient was asked to collect a faecal 
sample in the faecal collection bag, take a small amount from the bag with 
the spatula, put it in the test tube and seal it. The test tube with faecal 
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sample was to be put in the test tube holder, then in the cardboard box, 
which was to be put into the envelope and posted to the laboratory.  I 
advised them to post the sample within 24 hours of collection. Once I 
received the sample in the lab I would freeze it at -20°c. I would freeze all 
the samples until I had enough samples to run the ELISA. 
 
Before beginning my ELISA experiments I went to learn this technique at 
the Department of Biochemistry at Guy’s, King’s, St.Thomas Medical 
School, London under Dr. Roy Sherwood, where they were running the 
faecal calprotectin and lactoferrin ELISA routinely. After learning this 
technique in London my supervisor and I approached Dr.Dermat Neeley 
(Head of Department of Biochemistry, Newcastle upon Tyne Hospitals) to 
set up a facility for me to run this assay in Newcastle. Under the supervision 
of biochemist Mrs.J.Gicquel, I started to run the assay initially on healthy 
volunteers to master both techniques (FC and FL). Once I perfected the 
technique I began to do the experiments on actual patient samples 
independently. The techniques of the experiments are discussed in details 
in the following paragraphs and results of the experiments are discussed in 
detail in the results section of the thesis.  
 
The findings of this research project have been presented and published by 
myself in many medical and surgical meetings. I have discussed this in 
more detail in the publication section of this thesis. 
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2.2 Study design: 
This study involved investigation of two related arms: cross sectional and 
longitudinal studies. The Cross sectional study was used to determine 
whether faecal calprotectin and lactoferrin concentration measurement 
could identify gut inflammation in patients with symptomatic Crohn’s disease 
in the postoperative period and longitudinal study to monitor the trend of 
faecal calprotectin and lactoferrin concentrations in the immediate 
postoperative period of Crohn’s disease patients. This study was designed 
to be achievable in the time frame and within the budget available as well as 
acceptable to patients by virtue of not involving any invasive tests.  
 
2.3 Patient Selection: 
All patients included in both arms had a histological diagnosis of Crohn’s 
disease prior to inclusion and had an ileocaecal resection between January 
1982 and August 2007. All patients were recruited from medical and 
surgical gastroenterology clinics at Newcastle upon Tyne Hospitals NHS 
Foundation Trust. 140 patients in total were included in the study but 23 
patients were lost at the stage of faecal sample collection so a total of 117 
patients were studied. The demographics of the patients included are shown 
in table 3.1 in the results section of this thesis. The normal upper limit 
ranges for the faecal calprotectin (< 50 µg/g) and lactoferrin (< 7.25 µg/g) 
were well defined so a control group was not required in this study. The 
Gateshead and South Tyneside local research and ethics committee 
approval was obtained for the study reference number 06/Q0901/4. All 
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patients included in the study gave a written informed consent before 
inclusion in the study. An example of the patient information sheet and 
consent form is in the appendix of this thesis. 
 
2.3.1 Cross-sectional Study: 
 A total of 104 patients with a mean duration of 24 (range 2-300) months 
since surgery were recruited. All patients had undergone a previous 
ileocaecal resection for Crohn’s disease. The following clinical 
characteristics were recorded from patient’s notes and direct interview: age 
at disease or symptom onset, smoking history, sex, disease location, 
disease behaviour, pharmacology therapy and ileocolonoscopy findings 
(considered valid if performed within 4 weeks of patient interview). To 
estimate clinical disease activity Harvey Bradshaw Index Score [186] was 
also calculated for each patient. A Score <3 indicated clinically inactive, 4- 
mildly active, 5-moderately active and >6 severely active disease. Venous 
blood was obtained for white cell count (normal range 4.3-10×109/L), C-
reactive protein (< 5miligram/L) and platelets (normal range 150-350×109/L). 
On the same day a single stool sample for faecal calprotectin and lactoferrin 
was collected.  
 
2.3.2 Longitudinal Study: 
A total of 13 patients who had undergone ileocaecal resection were followed 
for 12 months for symptomatic Crohn’s disease. The following clinical 
characteristics were recorded from patient’s notes and direct interview: age 
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at disease or symptom onset, smoking history, sex, disease location, 
disease behaviour, current pharmacology therapy and ileocolonoscopy 
findings (considered valid if performed within 4 weeks of patient interview). 
Data on the complications, need for further interventions, postoperative 
course and outcome were collected. Serial stool samples including before 
surgery, at weekly intervals for 4 weeks and monthly intervals for 12 months 
were collected to determine the trends in faecal calprotectin and lactoferrin 
levels after surgery. 
 
2.4 Faecal sample collection and storage: 
Patients were taught to collect the faecal sample and a faecal sample 
collection bag along with the laboratory addressed postal kit (figure 2.1 & 
2.1a) was given to patients by me during their interview. For faecal 
calprotectin and lactoferrin levels, a single stool sample was used. The 
samples were stored at -20°C after collecting, labe lling until assays was 
performed. The assays were performed in the clinical biochemistry 
laboratory at Freeman Hospital, Newcastle upon Tyne NHS foundation 
Trust. Ten samples were obtained from healthy control patients without 
inflammatory bowel disease to confirm the quoted normal ranges for the two 
stool markers. 
Faecal calprotectin was measured using a commercially available 
(PhiCalTM; Calpro, Lysaker, Norway) quantitative enzyme immunoassay kit. 
Faecal lactoferrin was measured by (IBD-SCAN®; Techlab, Blacksburg, 
Virginia, USA) quantitative enzyme-linked immunosorbent assay. The 
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manufacturer’s guidelines were followed for the technique and 
measurements of both faecal calprotectin and faecal lactoferrin. These 
techniques have been successfully used in previous research projects [5, 
155, 183]. Venous blood was obtained for white cell count (normal range 
4.3-10 ×109/L), C-reactive protein (< 5miligram/L) and platelets (normal 
range 150-350 ×109/L).   
 
 
 
Figure 2.1 - Faecal sample collection kit. 
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Figure 2.1a - Faecal sample postal kit. 
 
2.5 Harvey-Bradshaw Activity Index: 
As most symptoms of Crohn’s disease broadly affect quality of life, attempts 
have been made to incorporate physical, social and emotional performance 
characteristics into tests for assessing severity of Crohn’s disease. While 
Crohn’s Disease Activity Index is considered closest to being gold standard 
but not been validated [187, 188]. A key criticism is that Crohn’s disease 
activity index does not incorporate a subjective assessment of quality of life, 
endoscopic factors or systemic features into calculation. Also it involves 
assessment over a period of seven days. Hence in this study much simpler 
version of the Crohn’s Disease Activity Index, Harvey Bradshaw Activity 
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Index was used. The Harvey Bradshaw Activity Index is a research tool 
used for quantifying the symptoms of patients with Crohn’s disease table 
2.2. The score ranges from 0 to 25, a score <3 indicated clinically inactive, 
4- mildly active, 5-moderately active and >6 severely active disease. It 
includes number of liquid stools, abdominal pain (0=none, 1=mild, 
2=moderate, 3=severe), general well being (0=very well, 1=slightly below 
par, 2=poor, 3=very poor, 4=terrible), abdominal mass (0=none, 1=dubious, 
2=definite, 3=definite and tender) and complications (arthralgia, uveitis, 
erythema nodosum, aphthous ulcers, pyoderma gangrenosum, anal fissure- 
score 1 per item) [186]. It is simpler than the CDAI score [189] which 
requires a 7 day symptom diary.    
 
Table 2.2 - Harvey Bradshaw Activity Index (HBI) 
General Well-being Very well=0 
Slightly below par=1 
Poor=2 
Very poor=3 
Terrible=4 
 
Abdominal pain None=0 
Mild=1 
Moderate=2 
Severe=3 
 
Number of liquid stools per day  
Abdominal mass None=0 
Dubious=1 
Definite=2 
Definite and tender=3 
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Complications  Arthralgia=1 
Uveitis=1 
Erythema nodusum=1 
Apthous ulcers=1 
Pyoderma gangrenosum=1 
Anal fissure=1 
New fistula=1 
Abscess=1 
 
 
 
2.6 Statistical Analysis: 
Power calculation and sample size for the study was confirmed after 
consultation with Newcastle University statistician (Prof Mathews). The 
minimum primary analysis for the cross-sectional study was to determine 
whether faecal measurements (of calprotectin and lactoferrin) were more 
likely to be elevated in active post-operative disease. In a population with 
40% inactive disease a sample size of 50 would be sufficient to detect a 
statistically significant association if the test is 80% effective at 
discriminating active disease from inactive disease. In this study over 100 
patients were available and the larger sample size gave the possibility to do 
much more detailed statistical testing as presented in the results section. 
The longitudinal study is essentially a case series to illustrate the value of 
sequential serial data, it is inappropriate for a sample size calculation and as 
it is limited by the availability of resections done during the study. 
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Sample size of one hundred patients in the cross-sectional study was 
sufficient to identify any clinically useful difference between faecal 
calprotectin and faecal lactoferrin. It was also sufficient to identify any 
clinically useful difference in faecal calprotectin and faecal lactoferrin 
concentrations between those with aggressive recurrent disease and those 
with indolent or inactive disease. 
 
The longitudinal study was a descriptive study looking at the time course of 
the faecal calprotectin and faecal lactoferrin changes in the post-operative 
time period. The sample size was ten patients as this reflects the selection 
of patients who will undergo surgery prospectively. 
 
SPSS® for Windows® version 15.0 (SPSS, Chicago, Illinois, USA) was used 
for data analysis. Kruskal-Wallis test was used for non-parametric data to 
identify significant differences in groups of continuous variables. To 
compare faecal calprotectin or faecal lactoferrin and continuous parameter, 
the Spearman’s rank order correlation (r) was used.    
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2.7 Method- faecal calprotectin experiment: 
The PhiCalTM; Calpro, Lysaker, Norway test is a commercially available kit, 
used as quantitative ELISA for measuring concentration of faecal 
calprotectin (figure 2.2) in this study.  
 
2.7.1 Principle of test: 
Antibodies to rabbit calprotectin are used in this ELISA. Once the faecal 
specimen extract is obtained and centrifuged, the sample is used for ELISA 
for faecal calprotectin. The rabbit antibodies react with at least 6 different 
epitopes on calprotectin which will ensure a positive signal even if some of 
the epitopes are destroyed by other substances in the stool. Hence a use of 
monoclonal antibodies involves a risk of giving false negative results and is 
not used in this assay. The PhiCalTM kit used for the test has microassay 
wells that contain polyclonal antibodies against calprotectin. Standards and 
serial dilutions of faecal specimens are put in the microassay wells. Later 
incubated for 45 minutes the wells are washed and antibody conjugate is 
added. During incubation period the conjugate binds with immunoaffinity 
purified anti-calprotectin. Again the wells are washed to remove any 
unbound material and substrate is added. If calprotectin is present the 
enzyme antigen-antibody complex will demonstrate a colour after a second 
incubation period of 20-30 minutes. Hence, the amount of enzyme bound is 
proportional to the amount of faecal calprotectin in the sample or standard, 
which can be determined after incubation with substrate for the enzyme. 
The test is run on stool extracts prepared by the use of patented extraction 
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buffer present in the kit. This buffer brings calprotectin present in stool into 
solution and has a molecular configuration similar to that of leukocytes 
extract or plasma. The reason for having similar configuration is important 
for this quantitative immunoassay. This assay requires both proteins in the 
standards and samples to have the same configuration. The standard curve 
is generated for calprotectin, sample values < 50 µg/g are considered 
negative and values of  ≥ 50µg/g are considered to be elevated. 
 
2.7.2 Contents of the kit and preparation of reagents: 
a) Extraction solution- the solution provided in the kit contains 2X 90ml 
of the 2.5X concentrate. To obtain 225ml of extraction solution 135 ml of 
distilled water is added and mixed well to use for the test. 
b) Washing solution- the solution provided in the kit contains 2X 50ml of 
the 20X concentrate. To obtain 1000ml of the washing solution 950ml of 
distilled water is added. 
c) Sample diluents solution- the solution contains 20ml of 10X 
concentrate. To obtain 200ml of diluents solution 180ml of distilled water is 
added. 
d) Enzyme conjugate antibody- the solution contains 16ml of alkaline 
phosphatise labelled immunoaffinity purified IgG antibodies from rabbit 
against calprotectin. It is a protein buffered solution containing sodium azide 
as a preservative. 
e) Enzyme substrate solution- the solution contains ready to use 16ml 
of substrate in buffer. 
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f) Standards- the solution contains 1.2ml of known concentrations of 
calprotectin. Total of 8 vials are provided with different concentrations 
(Standard A-7.8ng/ml, Standard B-15.6ng/ml, Standard C-31.3ng/ml, 
Standard D-62.5ng/ml, Standard E-125ng/ml, Standard F-250ng/ml, 
Standard G-500ng/ml and Standard H-1000ng/ml) as shown in the figure 
below.   
g) Control Solution- the solution 1.2ml of human calprotectin. The range 
of value is printed on the vial label and expressed in ng/ml. 
h) Stop solution- the solution contains 1M of NaOH. 
i) Microassay plate- it contains 12 strips and 8 wells in each strip. Each 
well is coated with polyclonal rabbit antibodies specific for calprotectin. The 
plate in a sealed bag with desiccant.  
 
Figure 2.2 - PhiCalTM kit; Calpro, Lysaker, Norway.  
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2.7.3 Faecal sample collection and preparation: 
Faecal samples of 1-5g received by post were stored at -20°C, if the test not 
performed within 48hrs. Approximately 100mg of faecal sample taken out, 
weighed with inoculation loop and prediluted extraction buffer is added to a 
weight/volume ratio 1:50 and mixed vigorously for 30 seconds. The sample 
along with extraction buffer is mixed on a shaker at approximately 1000 rpm 
for 30 minutes (figure 2.3). Then 1-2ml is transferred to a tube and 
centrifuged at 10000g for 20 minutes at +4°C for 20 minutes. The 
supernatant is the extract used to dilute and run for ELISA or could be 
stored at +4°C for several days or for 12 months if frozen. Therefore the 
extract is diluted in a ratio of 1:50 (20 µl faecal sample + 980 µl dilution 
buffer) before running the ELISA. Faecal samples with high concentrations 
are needed for re-testing after further dilution (1:5). 
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Figure 2.3 - Sample collection and preparation (PhiCalTM kit; Calpro, 
Lysaker, Norway).  
 
2.7.4 Assay procedure: 
Faecal samples are collected, prepared and thawed at room temperature. 
50 µl of diluted faecal sample, standard and control was added to wells as 
shown in the layout below (figure 2.4) and incubated at room temperature 
on a horizontal shaker for 45±5 mins. Later wells are washed with 250 µl 
washing buffer and this step is repeated for 5 washings. The plate is 
inverted and tapped on an absorbent tissue to remove washing buffer. After 
adding 50 µl of conjugate to each well, the plate is incubated at room 
temperature for 45±5 mins. Once the incubation period is completed the 
washing of the wells is repeated for 5 times again with the washing buffer. 
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100 µl of substrate is added using multi-channel pipette. The final incubation 
is carried out for 30 minutes in the dark until the optical density reading of 
the 1000ng/ml standard is 2.0 or stop solution is added to each well. The 
optical densities of all the wells are read on ELISA reader at 405 nm. 
 
 1 2 3 4 5 6 
A STANDARD H 
1000ng/ml 
STANDARD H 
1000ng/ml 
CONTROL CONTROL SPECIMEN 8 SPECIMEN 8 
B STANDARD G  
500ng/ml 
STANDARD G  
500ng/ml 
SPECIMEN 1 SPECIMEN 1 SPECIMEN 9 SPECIMEN 9 
C STANDARD F  
250ng/ml 
STANDARD F  
250ng/ml 
SPECIMEN 2 SPECIMEN 2 SPECIMEN 10 SPECIMEN 10 
D STANDARD E  
125ng/ml 
STANDARD E  
125ng/ml 
SPECIMEN 3 SPECIMEN 3 SPECIMEN 11 SPECIMEN 11 
E STANDARD D 
62.5ng/ml 
STANDARD D  
62.5ng/ml 
SPECIMEN 4 SPECIMEN 4 SPECIMEN 12 SPECIMEN 12 
F STANDARD C 
31.3ng/ml 
STANDARD C  
31.3ng/ml 
SPECIMEN 5 SPECIMEN 5 SPECIMEN 13 SPECIMEN 13 
G STANDARD B          
15.6 ng/ml  
STANDARD B    
15.6ng/ml 
SPECIMEN 6 SPECIMEN 6  SPECIMEN 14 SPECIMEN 14 
H STANDARD A   
7.8ng/ml 
STANDARD A   
7.8ng/ml 
SPECIMEN 7 SPECIMEN 7 SPECIMEN 15 SPECIMEN 15 
Figure 2.4 - Plate template layout of test samples- including calprotectin 
standards, control and faecal specimens (PhiCalTM kit; Calpro, Lysaker, 
Norway). 
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2.7.5 Calculation of faecal calprotectin results: 
The concentration of faecal calprotectin in all the wells is calculated by a 
computer linked ELISA reader (4-parameter or spline function) or manually. 
The mean optical densities of all the duplicate wells are calculated. To 
obtain a standard curve a graph is plotted using log values of the standards 
against their own optical densities (as shown in figure below), control value 
readings should be within the value printed on the bottle (as shown in the 
figure 2.5). The values of the faecal samples from the standard curve are 
corrected for dilution and converted to mg/kg by multiplying by 2.5 and the 
additional dilution factor is entered if faecal samples are further diluted 
during calculation. Faecal samples giving readings above 50µg/g are 
regarded as positive for calprotectin 
 
Figure 2.5 - Calprotectin standard curve for optical density of 405 nm 
(PhiCalTM kit; Calpro, Lysaker, Norway). 
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2.8 Method- Faecal lactoferrin experiment: 
The ELISA IBD-SCAN® ( Techlab, Blacksburg,Virginia,USA) test is a 
commercially available quantitative test for measuring concentrations of 
faecal lactoferrin which is a marker of faecal leukocytes [161] (figure 2.6) 
used in this study.  
 
2.8.1 Principles of test: 
Antibodies to human lactoferrin are used in this test. The IBD-SCAN®; 
Techlab kit used for the test has microassay wells that contain immobilised 
polyclonal antibody against lactoferrin. The detecting antibody is made of 
polyclonal antibody conjugated to horseradish peroxidise. Standards and 
serial dilutions of the faecal specimens are put in the microassay wells. The 
faecal lactoferrin binds to immobilised antibody if there are measurable 
levels of lactoferrin in the faecal specimen. After 30 minutes of incubation 
the wells are washed and antibody conjugate is added. During this 
incubation period the conjugate binds to the lactoferrin. Again the wells are 
washed to remove any unbound material and substrate is added. If 
lactoferrin is present the enzyme antigen-antibody complex will demonstrate 
a colour after a second incubation period of 15 minutes. The concentration 
of lactoferrin present is directly proportional to absorbance measured. The 
standard curve generated for lactoferrin ranges from 6.25 to 100 ng/ml. 
Lactoferrin concentration can be determined in a test sample by plotting 
absorbance values against lactoferrin concentrations.    
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2.8.2 Contents of the kit and preparation of reagents: 
a) Diluent- the solution contains 10X concentrate of  a buffered protein 
solution containing 0.2% thimersol.40 ml of diluents is supplied as a 10X 
concentrate in the kit. 360ml of deionised water is added to 40 ml provided 
to dilute to obtain a total volume of 400ml. The 1X diluent is used as 
negative control. 
b) Wash buffer solution- the solution contains 20X concentrate of 
phosphate buffered saline, detergent and 0.2% thimersol. 50ml is supplied 
as a 20X concentrate in the kit. 950 ml of deionised water is added to the 50 
ml provided to obtain a total volume of 1 litre. 
c) Conjugate- the solution contains 7 ml of rabbit polyclonal antibody 
specific for human lactoferrin conjugated to horseradish peroxidise. It is in a 
buffered protein solution containing 0.02% thimerosal. 
d) Substrate- the solution contains 14ml of tetramethylbenzidine 
substrate and peroxide. 
e) Standards- the solution contains 1.5 ml of human lactoferrin 
standard. It is in a buffered protein solution contacting 0.02% thimerosal. 
Total of 5 standard solutions are provided with different concentration (LS1- 
100ng/ml, LS2-50ng/ml, LS3-25ng/ml, LS4-12.5ng/ml and LS5-6.25ng/ml) 
as shown in figure below. 
f) Positive control- the solution contains 1.5ml (10µg/ml) of human 
lactoferrin. It is in protein buffered solution containing 0.02% thimerosal. 
1:10 and 1:200 dilution of positive control is prepared in two tubes. Two 
tubes containing 450 µl & 950 µl of 1X diluents are taken. 50 µl of positive 
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control is added to tube 1 and 50 µl from tube 1 to tube 2. Both the tubes 
are vortex for 10 seconds and stored between 2 & 8°C till ELISA performed. 
Therefore tube 1 contains 1:10 and tube 2 contains 1:200 dilution of positive 
control.  
g) Stop solution- the solution contains 7ml of sulphuric acid. 
h) Microassay plate- it contains 12strips and 8 wells in each strip. Each 
well is coated with purified polyclonal antibody for lactoferrin.      
 
 
Figure 2.6 - IBD-SCAN® kit; Techlab, Blacksburg, Virginia, USA.  
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2.8.3 - Faecal sample collection and preparation: 
Once a faecal sample is received by post it is stored at -20°C, if the test is 
not performed within 48 hrs. The diluted faecal sample is prepared by 
setting up 3 tubes for 1:10 and 1:200 concentrations. 450µl of diluents is 
added to three tubes and 50µl or 0.05g of faecal specimen is added to tube 
one and mixed. Then 50µl is transferred from tube 1 to tube 2 and mixed 
well and finally 50µl is transferred from tube 2 to tube 3 mixed well on a 
vortex mixer. Therefore tube 1 contains 1:10, tube 2 contains 1:100 and 
tube 3 contains 1:1000 diluted faecal samples for the assay.   
  
2.8.4 Test procedure: 
Materials provided in the kit are shown in the figure 2.6 also contains 2 
plastic adhesive sheets and 100 transfer pipettes. Other materials required 
for the experiment are a refrigerator for storage, discard container/absorbent 
paper, distilled water, squirt bottle for wash buffer solution, vortex mixer, 
tubes for dilution of specimen, bottle for diluents, pipettes and ELISA reader 
(450 nm or 450/620 nm). Following the completion of preparing diluent, 
wash buffer, positive control, and negative control and diluted faecal 
specimen the ELISA using the microassay plate is started.  Using 
designated and two wells for each standard, one well for 1:200 dilution of 
positive control, one well for negative control (1X diluent) and one well for 
faecal specimen dilutions 1:100 and 1:1000 as shown in the figure 2.7. 
 
 
 Chapter 2 – Materials and Methods 
83 
 
 1 2 3 4 5 6 
A NEGATIVE 
CONTROL 
POSITIVE 
CONTROL(100) 
SPECIMEN3 
(100) 
SPECIMEN3 
(1000) 
SPECIMEN11 
(100) 
SPECIMEN11 
(1000) 
B STANDARD
1 
STANDARD1 SPECIMEN4 
(100) 
SPECIMEN4 
(1000) 
SPECIMEN12 
(100) 
SPECIMEN12 
(1000) 
C STANDARD
2 
STANDARD2 SPECIMEN5 
(100) 
SPECIMEN5 
(1000) 
SPECIMEN13 
(100) 
SPECIMEN13 
(1000) 
D STANDARD
3 
STANDARD3 SPECIMEN6 
(100) 
SPECIMEN6 
(1000) 
SPECIMEN14 
(100) 
SPECIMEN14 
(1000) 
E STANDARD
4 
STANDARD4 SPECIMEN7 
(100) 
SPECIMEN7 
(1000) 
SPECIMEN15 
(100) 
SPECIMEN15 
(1000) 
F STANDARD
5 
STANDARD5 SPECIMEN8 
(100) 
SPECIMEN8 
(1000) 
SPECIMEN16 
(100) 
SPECIMEN16 
(1000) 
G SPECIMEN
1 
(100) 
SPECIMEN1 
(1000) 
SPECIMEN9 
(100) 
SPECIMEN9 
(1000) 
SPECIMEN17 
(100) 
SPECIMEN17 
(1000) 
H SPECIMEN
2 
(100) 
SPECIMEN2 
(1000) 
SPECIMEN10 
(100) 
SPECIMEN10 
(1000) 
SPECIMEN18 
(100) 
SPECIMEN18 
(1000) 
Figure 2.7 - Plate template layout of test samples- including lactoferrin 
standards, positive and negative control and faecal specimens (IBD-
SCAN®; Techlab, Blacksburg, Virginia, USA). 
 
100µl of each standard (LS1-LS5) is added using a calibrated pipette to 
duplicate wells and 100µl of negative control (1X diluents) and positive 
control (1:100) is added to designate wells as shown in the table 2.7 above. 
Also 100µl of faecal specimen diluted is added using a fresh pipette to 
separate wells (1:100 & 1:1000 dilution). The wells are covered with 
adhesive plastic sheet and incubated at 37°C ±2°C f or 30 minutes.  
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Once the incubation period is completed for 30 minutes the contents of the 
assay wells are discarded and each well is washed for five times using 1X 
wash solution using the squirt bottle. The direction of wash solution should 
be towards the bottom of the well with force and the plate is inverted on dry 
absorbent paper and slapped each time of wash. The washing should be 
continued if any particulate matter is seen in the wells until it is cleared from 
the well. One drop of conjugate is added provided in the red cap for all the 
wells and further incubated for 30 minutes at 37°C ±2°C. Later, after 
incubation the washing of wells is repeated as before for five times and 
dried on absorbent paper. 
 
Two drops of substrate are added into each of the wells and incubated for 
fifteen minutes at room temperature. Gentle tapping of wells is done one to 
two times to mix the contents during the incubation period. Finally one drop 
of stop solution is added and rested for 2 minutes before reading of plate is 
done. This addition of stop solution converts the blue colour of the solution 
to yellow and the optical density is then quantitatively measured at 450 nm 
or 450/620 nm on ELISA plate reader. The reading of plate is done within 2 
to 10 minutes of adding stop solution. All the absorbance values are 
recorded for the standards, positive and negative control and each faecal 
specimen. Lastly, before interpreting of the results, the average value is 
taken of the duplicate wells. The quality control of the assay is assessed 
and should have values of negative control optical density of <0.100 for 450 
nm and <0.060 for 450/620 nm and positive control value of 10±3 µg/ml. 
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The R2 value should be ≥ 0.98 when the linear trend/regression type 
analysis is used and if the graph is followed then the points should be in a 
straight line as shown figure 2.8. 
                      
Figure 2.8 - Lactoferrin standard curve for optical density of 450 nm (IBD-
SCAN®; Techlab, Blacksburg, Virginia, USA). 
 
2.8.5 Calculation of faecal lactoferrin results: 
Using linear trend/regression type analysis on an appropriate data reduction 
computer programme optimal estimation of faecal specimen values is 
obtained. The most diluted specimen giving values within the standard 
curve if optical density 450 nm ≥ 0.100 and optical density 456/620 nm ≥ 
0.060 is chosen. The test is repeated using dilution of 1:10 if both the 
sample dilutions have values greater than the highest concentration of 
standard. Any specimen value showing less than the lowest concentration 
should also be retested using dilution of 1:10. If the result is found to be 
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negative then it’s recorded as < 1µg/g. The average values obtained for 
standards are plotted on y-axis and the concentrations are plotted on x-axis 
to perform the linear/regression analysis. The R2 value obtained should be ≥ 
0.98. 
The programme to produce the equation (Y=MX+B) for the plotted line is 
inserted in the computer, where X equals concentration of unknown 
specimen, M equals slope, B equals Y-intercept and Y equals optical 
density 450 nm or 450/620 nm of the specimen. Later X is determined as 
the concentration of the faecal lactoferrin in the specimen and multiplied by 
dilution factor (which could be 10 for 1:10 dilution, 100 for 1:100 and 1000 
for 1:1000 dilutions) and divided by 1000 to convert ng/ml to µg/ml. The 
value obtained for lactoferrin in the faecal specimen is interpreted to be 
normal if it is between 0-7.24 µg/ml and elevated if ≥ 7.25 µg/ml. 
The limitations of the IBD-SCAN® are as follows: it could only be used in 
faecal specimen as other types of clinical specimens are not evaluated, not 
to be used in immuno-compromised patients or with patients with history of 
ileostomy formation within 1 month or history of infectious diarrhoea or 
faecal specimen preserved in formalin or patients with colorectal cancer as 
this gives high values. 
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3.1 Introduction: 
To determine whether faecal calprotectin and faecal lactoferrin 
concentration measurement could identify gut inflammation in patients with 
symptomatic post-operative Crohn’s disease. Patients had to have a 
histological diagnosis of Crohn’s disease to be included in the study and 
had to have ileocaecal resection. The study period included patients who 
have had resection between January 1982 and August 2007. From the 
medical and surgical gastroenterology clinics at Newcastle upon Tyne 
Hospitals NHS Foundation Trust patients were identified for the study. 
 
3.1.1 Aim: 
This study involved investigation of two related arms: cross sectional and 
longitudinal studies. The Cross sectional study results address the following 
four aims of the study. 
Quantitative measurement of faecal markers faecal calprotectin and faecal 
lactoferrin may offer a valuable method as non-invasive markers in 
assessing the symptomatic post-operative patient in Crohn’s disease. 
To investigate this hypothesis this study had the following aims: 
1. To determine whether faecal calprotectin and faecal lactoferrin 
measurements in symptomatic post-operative Crohn’s patient can 
differentiate those with aggressive disease from those with benign 
disease. 
2. To compare faecal calprotectin and faecal lactoferrin with other 
measurements of inflammatory activity such as C-reactive protein, 
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white cell count, platelet count, clinical disease activity index (HBI) 
and endoscopic finding. 
3. To determine how faecal calprotectin and faecal lactoferrin correlate 
with each other after resection. 
 
3.2 Materials and Methods: 
3.2.1 Clinical Data: 
A total of 104 patients with a mean duration of 24 (range 2-300) months 
since surgery were recruited. All patients had undergone a previous 
ileocaecal resection for Crohn’s disease. The following clinical 
characteristics were recorded from patient’s notes and direct interview: age 
at disease or symptom onset, smoking history, sex, disease location, 
disease behaviour, pharmacology therapy and ileocolonoscopy findings 
(considered valid if performed within 4 weeks of patient interview). To 
estimate clinical disease activity Harvey Bradshaw Index Score was also 
calculated for each patient. A Score <3 indicated clinically inactive, 4- mildly 
active, 5-moderately active and >6 severely active disease. Venous blood 
was obtained for white cell count (normal range 4.3-10 ×109/L), C-reactive 
protein (< 5miligram/L) and platelets (normal range 150-350 ×109/L). On the 
same day a single stool sample for faecal calprotectin and lactoferrin was 
collected.  
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3.2.2 Stool sample collection: 
This has been described in detail in material and methods chapter of this 
thesis. 
 
3.3 Results:  
3.3.1 Faecal calprotectin and faecal lactoferrin, blood parameters and 
Harvey Bradshaw Index clinical disease activity: 
Clinical characteristics of the patients are shown in table-3.1. 140 patients 
were invited to participate in the cross sectional study but 23 were lost at the 
stage of stool collection. 104 patients participated in the cross sectional 
study with male to female ratio 43:61 and their median age at study was 45 
(18-79) years and the remaining 13 patients are included in longitudinal 
study. The median follow up since ileocaecal resection is 12 (1-40) years. 
All patients had open ileo-colic resection since January 1999 and August 
2007. 
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Table 3.1 - Demographic and clinical profile of cross sectional study group. 
  Cross sectional 
Total number of patients in study 
group 
 104 
Sex (M:F)  43:61 
Mean age in years (range)  45 (18-79) 
Mean duration of disease in years 
(range)* 
 12 (1-40) 
Time after ileocaecal resection in 
months (range) 
 24 (2-300) 
Disease Location Ileal 71 
 Ileo-Colic 28 
 Perianal disease† 5 
Disease Behaviour Inflammatory 17 
 Stenosing 51 
 Perforating 31 
 Perianal Fistula† 5 
Smoking Status Never 31 
 Ex-smokers 32 
 Current 41 
Endoscopy (< 1month at follow up) Recurrence 25/43 
 No recurrence 18/43 
Maintenance Therapy No medications 33 
 5 – aminosalicylic 10 
 Corticosteroids 23 
 Azathioprine 39 
 Methotrexate 11 
 TNF- alpha antagonist 3 
* Values are median (range). †Perianal disease present in combination with 
ileal or ileo-colic disease. 
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The mean (±SE) calprotectin levels in this cohort of patients with Crohn’s 
disease was 300 µg/g (± 44.6), lactoferrin 12.02µg/g (± 12), CRP 19.15 
mg/L (± 4.28), white cell count 8.51 mg/L (± 0.31) and platelet count 304 (± 
8.23) as shown in table-3.2. Both faecal calprotectin and lactoferrin 
correlated significantly with the HBI definition of clinical disease activity (r = 
0.532, P< 0.001, r = 0.687, P< 0.001 respectively). CRP level also showed a 
significant but weak correlation with current disease activity (r = 0.329; P 
<0.001). Based on Harvey Bradshaw index score, 28 patients had clinically 
active disease (HBI ≥6) and 43 had inactive (HBI≤3), 19 had mildly active 
(HBI = 4) and 14 patients had moderately active disease (HBI = 5). All 
patients with severely clinically active disease (28/104) had high faecal 
calprotectin level 661.1µg/g (±119.1), faecal lactoferrin level 116.6µg/g 
(±32.21), CRP 44.54mg/L (±14.34) compared with clinically inactive group 
{calprotectin 70.18 µg/g (±27.12), lactoferrin 5.92 µg/g (±2.39), CRP 7.72 
mg/L (±1.67)} figure 3.1 and 3.2. The logarithmic distribution of faecal 
calprotectin and lactoferrin related to HBI is shown in Figure 3.3 and 3.4 
respectively. 
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Table 3.2 - Correlation of faecal, serum parameters and Harvey Bradshaw 
Index clinical activity. 
Clinical 
activity (HBI 
score) 
& Patients 
numbers (n=) 
Faecal 
Calprotectin 
levels (µg/g) 
Mean±SE 
Faecal 
Lactoferrin levels 
(µg/g) Mean±SE 
White cell 
count 
(×109/L) 
Mean±SE 
CRP (mg/l) 
Mean±SE 
Platelet count 
(×109/L) 
Mean±SE 
None (<3) 
n= 43 
70.2(±27.1) 5.9(±2.4) 7.5(±0.3) 7.7(±1.7) 311.7(±13.7) 
Mild (4) 
n = 19 
 
333.7(±78.9) 51.3(±14.8) 8.8(±0.8) 14.6(±5.2) 271.5(±15.1) 
Moderate (5) 
n = 14 
242.4(±79.2) 77.8(±50.4) 8.4(±0.6) 9.7(±2.5) 310.3(±16.1) 
Severe (>6) 
n = 28 
661.1(±119.1) 116.6(±32.2) 9.9(±0.8) 44.5(±14.3) 311.0(±17.8) 
P value 
Kruskal Wallis 
test 
p=0.0001 p=0.0001 p=0.1085 p=0.0006 p=0.2769 
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Figure 3.1 - Mean values of faecal calprotectin in correlation with HBI score. 
Horizontal bars represent mean values of faecal calprotectin. 
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Figure 3.2 - Mean values of faecal lactoferrin in correlation with HBI score. 
Horizontal bars represent mean values of faecal lactoferrin. 
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Figure 3.3 - Faecal calprotectin-logarithmic distribution related to HBI score. 
Horizontal line represent normal value of faecal calprotectin = 50 µg/g.  
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Figure 3.4 - Faecal lactoferrin-logarithmic distribution related to HBI score 
(p<0.001). Horizontal line represent normal value for faecal lactoferrin= 7.25 
µg/g.  
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3.3.2 Heterogeneous Group: 
The mean faecal calprotectin, lactoferrin levels and HBI were compared in 
high versus low levels of gut inflammation, which was arbitrarily defined by 
faecal calprotectin (100 µg/g) or lactoferrin (14.5 µg/g) values of more or 
less than twice (table-3.3) the upper limit of normal (ULN). Those who were 
clinically asymptomatic or had inactive disease (HBI≤3) had low mean 
faecal calprotectin and faecal lactoferrin values demonstrating inactive gut 
inflammation. Patients with high levels of clinically symptomatic or severely 
active disease (HBI≥6) tend to have higher levels of faecal calprotectin and 
faecal lactoferrin corresponding to highly active gut inflammation. Those 
with clinically mild to moderate disease activity (HBI 4-5) were far more 
heterogeneous. The patients having high or low levels of gut inflammation 
as defined above were almost equal in number. Thus faecal calprotectin 
and faecal lactoferrin allowed identifying two groups with very different 
biomarker levels of gut inflammation with similar clinical severity index.  
 
In heterogeneous group (figure 3.5 and 3.6) of patients {Mild (19) Vs 
Moderate (14)} levels of faecal calprotectin, faecal lactoferrin, white cell 
count, platelet count and CRP were abnormal but did not correlate 
significantly with disease activity (table- 3.4). 
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Figure 3.5 - Faecal calprotectin in heterogeneous group (mild & moderate). 
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Figure 3.6 - Faecal lactoferrin level in heterogeneous group (mild & 
moderate). 
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Table 3.3 - Correlation between high and low levels of gut inflammation 
defined by faecal markers and Harvey Bradshaw clinically disease activity 
index. 
 Pts 
n=104 
Faecal 
Calprotectin 
(FC µg/g) 
 
Faecal 
Lactoferrin 
(FL µg/g) 
HBI(≤3) 
n=43 
HBI(4-5) 
n=33 
HBI(≥6) 
n=28 
FC(<100 µg/g) 
2 xULN 
64 28 - 37 17 10 
FC(>100 µg/g) 
2 xULN 
40 737 - 6 16 18 
FL(<14.5 µg/g) 
2 xULN 
62 - 4 41 15 6 
FL(>14.5 µg/g) 
2 xULN 
42 - 127 2 18 22 
 
 
Table 3.4 - Heterogeneous group. 
Disease Activity Mild (HBI=4) 
N=19 
Moderate(HBI=5) 
N=14 
p-value (Spearman’s 
correlation coefficient) 
Faecal Calprotectin 333.7(±78.87) 242.4(±79.15) p=0.138             (r = -.264) 
Faecal Lactoferrin 51.28(±14.75) 77.8(±50.37) p=0.497            (r = -.122) 
White cell count(×109/L) 8.81(±0.85) 8.43(±0.60) p=0.901             (r = -.023) 
CRP(mg/l) 14.58(±5.19) 9.71(±2.46) p=0.557             (r = -.106) 
Platelet count(×109/L) 271.5(±15.08) 310.3(±16.08) p=0.128             (r = -.271) 
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3.3.3 Faecal markers and endoscopic activity: 
43 out of 104 patients had endoscopic assessment up to 4 weeks before the 
direct patient interview. Out of these, 25 had endoscopic proven disease 
recurrence. Mean (±SE) values (table-3.5) of white cell count, platelet count 
and CRP were not significant with absence of disease (P = 0.0815). There 
was no significant difference between mean (±SE) values of faecal 
calprotectin and lactoferrin with endoscopic disease recurrence and those 
without endoscopic disease recurrence (P=0.676 and P=0.73 respectively).   
 
There was no significant Spearman’s correlation between faecal calprotectin 
and faecal lactoferrin with no endoscopic recurrence (18/43) and with 
endoscopic recurrence (25/43) (figure 3.7 and 3.8).  
 Chapter 3 – Cross Sectional Study Results 
102 
 
 
Figure 3.7 - Correlation of faecal calprotectin and lactoferrin with no 
endoscopic recurrence. 
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Figure 3.8 - Correlation of faecal calprotectin and lactoferrin with 
endoscopic recurrence. 
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Table 3.5 - HBI score, serum parameter and faecal marker levels in patients 
with and without endoscopic disease recurrence. 
N=43/104 Endoscopic-  no disease 
recurrence (18/43) 
Endoscopic- disease recurrence  
(25/43) 
Faecal calprotectin (µg/g) 
Mean±SE 
295(±82.69) 395(±135.3) 
Faecal Lactoferrin (µg/g) Mean±SE 76.81(±36.81) 88.91(±41.76) 
Platelet count (×109/L) Mean±SE 325.9(±17.19) 331.8(±14.35) 
White cell count (×109/L) Mean±SE 8.72(±.64) 8.61(±.59) 
CRP (×109/L) Mean±SE 16(±5.86) 22.83(±11.93) 
HBI score  ≤ 3 9 8 
HBI score 4-5 7 8 
HBI score ≥ 6 2 9 
Kruskal-Wallis test - p value = 0.0815 
 
3.3.4 Faecal markers and smoking status: 
Out of total 104 patients, 41 were current smokers, 32 former smokers and 
31 who had never smoked. No significant difference was found between 
smokers and non smokers in the faecal calprotectin (P= 0.284) and faecal 
lactoferrin (P= 0.612) using Mann-Whitney U test. 
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3.3.5 Faecal markers and maintenance therapy: 
The 104 patients included 23 patients who received corticosteroid therapy 
and 39 of which received azathioprine. There was no significant difference 
in the levels of  faecal calprotectin, lactoferrin, white cell count, platelets and 
CRP between patients, who are on azathioprine (P=0.082), corticosteroids 
(P=0.159) and methotrexate (P=0.082). 
 
3.3.6 Correlation between faecal calprotectin and faecal lactoferrin:  
A total of 259 stool samples were used in both cross sectional (104) and 
longitudinal study (155). Using Spearman’s correlation both faecal 
calprotectin and lactoferrin values showed significant correlation with each 
other (r = 0.71, P <0.001) (figure 3.9).  
Sub-group analysis in an individual group of clinical disease activity (none, 
mild, moderate and severely active, based on HBI) was performed in cross-
sectional study. This was done to identify if any difference exists between 
faecal calprotectin and faecal lactoferrin in this individual group. Both faecal 
calprotectin and lactoferrin showed significant correlation with each other 
(figure 3.10, 3.11, 3.12 and 3.13). This show both faecal calprotectin and 
faecal lactoferrin were comparable with disease activity. 
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Figure 3.9 - Correlation of faecal calprotectin and lactoferrin in all stool 
samples. 
 
 
 
 
 
 
 
 
Spearman’s    r=0.71, p<0.0001 
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Figure 3.10 - Correlation of faecal calprotectin and lactoferrin in patients 
with HBI<3 (n=43). 
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Figure 3.11 - Correlation of faecal calprotectin and lactoferrin in patients 
with HBI=4 (n=19). 
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Figure 3.12 - Correlation of faecal calprotectin and lactoferrin in patients 
with HBI-5 (n=14). 
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Figure 3.13 - Correlation of faecal calprotectin and lactoferrin in patients 
with HBI>6 (n=28). 
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4.1 Introduction: 
To determine whether faecal calprotectin and faecal lactoferrin 
concentration measurement could identify gut inflammation in patients with 
symptomatic post-operative Crohn’s disease and to monitor the trend of 
postoperative faecal calprotectin and lactoferrin levels. Patients had to have 
a histological diagnosis of Crohn’s disease to be included in the study and 
were going to have ileocaecal resection for symptomatic Crohn’s disease. 
The study period included patients who went for ileocaecal resection 
between August 2006 and August 2007 and followed for 12 months post 
resection. From the medical and surgical gastroenterology clinics at 
Newcastle upon Tyne Hospitals NHS Foundation Trust patients were 
identified for the study. 
 
4.1.1 Aim: 
The longitudinal study result addresses the following aims of the study. 
Quantitative measurement of faecal markers, faecal calprotectin and faecal 
lactoferrin may offer a valuable method as non-invasive markers in 
assessing the individual post-operative patient in Crohn’s disease. 
To investigate this hypothesis this study had the following aims: 
1) To determine the immediate post-operative course of faecal 
calprotectin and faecal lactoferrin after ileocaecal resection. 
2) To determine whether these faecal markers could demonstrate 
inflammatory activity and identify post-operative disease recurrence.  
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3) To identify if there is a difference in this two markers among 
uncomplicated and complicated group (with post-operative 
complications like anastomotic leak, intra-abdominal collection, 
wound infection and disease recurrence)   of patients in immediate 
post-operative setting. 
  
4.2 Materials and Method: 
4.2.1 Clinical data: 
A total of 13 patients who had undergone ileocaecal resection were followed 
for 12 months for symptomatic Crohn’s disease. The following clinical 
characteristics were recorded from patient’s notes and direct interview: age 
at disease or symptom onset, smoking history, sex, disease location, 
disease behaviour, current pharmacology therapy and ileocolonoscopy 
findings (considered valid if performed within 4 weeks of patient interview). 
Data on the complications, need for further interventions, postoperative 
course and outcome were collected. Serial stool samples including before 
surgery, at weekly intervals for 4 weeks and monthly intervals for 12 months 
were collected to determine the trends in faecal calprotectin and lactoferrin 
levels after surgery. 
 
4.2.2 Stool sample collection: 
This has been described in detail in material and methods chapter of this 
thesis. 
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 4.3 Results: 
4.3.1 Longitudinal study: 
A group of 13 patients were included in this study. This group set up was to 
determine the course of faecal calprotectin and lactoferrin immediately after 
surgery. 155 stool samples were collected in this group. The demographic 
and clinical profile of longitudinal study group is shown in table – 4.1. Mean 
(± SE) pre-operative levels of both faecal calprotectin (879 µg/g ± 174.5) 
and lactoferrin (398.9 µg/g ± 164.5) were significantly high in all patients in 
this group. 
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Table 4.1 - Demographic and clinical profile of longitudinal study group. 
  Longitudinal 
Total number of patients in study 
group 
 13 
Sex (M:F)  4:9 
Mean age in years (range)  34 (18-64) 
Mean duration of disease in years 
(range) 
 8 (1-30) 
Disease Location Ileal 10 
 Ileo-Colic 3 
 Perianal disease 1 
Disease Behaviour Inflammatory 3 
 Stenosing 7 
 Perforating 3 
 Perianal Fistula 1 
Smoking Status Never 5 
 Ex-smokers 3 
 Current 5 
Endoscopy (< 1month at follow up) Recurrence 3/4  
 No recurrence ¼ 
Maintenance Therapy No medications 5 
 5 – aminosalicylic 3 
 Corticosteroids 4 
 Azathioprine 8 
 Methotrexate 2 
 TNF- alpha antagonist 2 
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4.3.2 Uncomplicated post-operative recovery patients: 
Uncomplicated group of patients are those patients without any post-
operative complications like anastomotic leak or intra-abdominal collection 
or wound infection or disease recurrence. 8 of 13 patients had an 
uncomplicated postoperative recovery. Mean (± SE) of faecal calprotectin 
and lactoferrin were highest before surgery, at 562(155.7) µg/g and 
347.7(159.0) µg/g respectively, but fell quickly after resection (table-4.2). 
Both markers normalised by 2 months and remained within normal limits 
during the entire study period. Both faecal calprotectin and lactoferrin levels 
variation with time was similar in each patient. The individual trends and 
median values for each patient are shown in figure 4.1, 4.1a, 4.2 and 4.2a. 
Out of these 8 uncomplicated patients only one patient had an unexplained 
increase in faecal calprotectin and lactoferrin level. This patient had a high 
pre-operative level of 1035.8µg/g and 248.7µg/g respectively, which 
normalised by two weeks and increased to 61µg/g and 19.1µg/g before 
spontaneously normalising at 12 months. 
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Table 4.2 - Faecal calprotectin and lactoferrin levels before and after 
resection in 8 patients with an uncomplicated recovery. 
 Faecal Calprotectin 
Mean(± SE) (µg/g) 
Faecal lactoferrin 
Mean(± SE) (µg/g) 
Before Surgery 562.0 (155.7) 347.7 (159.0) 
1 week 334.3 (114.2) 91.1 (68.0) 
4 weeks 20.8 (12.4) 2.7 (0.7) 
2 months 8.7 (2.8) 3.4 (0.7) 
3 months 4.7 (2.7) 2.1 (0.7) 
6 months 3.0 (0.9) 3.0 (0.8) 
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Figure 4.1 - Faecal calprotectin levels (individual values) pre-operative and 
at post-operative follow up of 8 patients with an uncomplicated post-
operative recovery. 
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Figure 4.1a - Faecal calprotectin levels (median values) pre-operative and 
at post-operative follow up of 8 patients with an uncomplicated post-
operative recovery. 
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Figure 4.2 - Faecal lactoferrin levels (individual values) pre-operative and at 
post-operative follow up of 8 patients with an uncomplicated post-operative 
recovery. 
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Figure 4.2a - Faecal lactoferrin levels (median values) pre-operative and at 
post-operative follow up of 8 patients with an uncomplicated post-operative 
recovery. 
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4.3.3 Complicated post-operative recovery patients: 
Complicated patients are those patients with post-operative complications 
like anastomotic leak or intra-abdominal collection or wound infection and 
disease recurrence. 5 out of 13 patients had complications following 
ileocaecal resections (figure 4.3, 4.3a, 4.4 and 4.4a). Individual patient 
profile for the 5 complicated post-operative recovery patients is shown in 
table 4.3. A 58 year old male Patient A developed an intra-abdominal 
abscess one month after ileocaecal surgery. This patient had a pre-
operative faecal calprotectin level of 519.8 µg/g. This quickly normalised but 
increased to 263.1µg/g at one month coinciding with leak after surgery. A 
pre-operative faecal lactoferrin level of 37.9µg/g normalised but then 
increased by the time of complication to 121.5µg/g. After surgical repair both 
these markers normalised within one month.  
 
Second Patient B was a 69 year old female who developed a leak and intra-
abdominal collection in the 2nd week after ileocaecal resection, underwent a 
laparotomy for drainage and made a good recovery. At the time of her 
complication her faecal calprotectin level climbed from 30.5µg/g to 1616µg/g 
and her faecal lactoferrin level increased from 5.8µg/g to 680.8µg/g. Both 
markers normalised one month after drainage of abscess. 
 
Third Patient C was a 25 year old female who developed clinical and 
endoscopic recurrence as well as wound infection within one month of 
ileocaecal resection. Her preoperative faecal calprotectin level was 
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1616.8µg/g which fell slightly to 1344.5µg/g and then increased to 
1607.0µg/g when she relapsed. Her preoperative faecal lactoferrin level of 
179.5µg/g normalised after surgery to 5.2µg/g and then increased to 
116.8µg/g at the time of relapse. After she was started on azathioprine and 
treatment for a wound infection, faecal markers normalised over three 
months time. 
 
Fourth Patient D was a 21 year old male patient who had relapsed at 9 
month, his pre-operative faecal calprotectin (1127.4µg/g) and lactoferrin 
(61.2µg/g) levels normalised by one month and at the time of his symptoms 
flare up went up to 78.9µg/g and 22.1µg/g needing azathioprine therapy. His 
levels had been consecutively high from month five onwards. 
 
Fifth Patient E was a 34 year old male patient who had ileocolonic and 
perianal disease. His pre-operative faecal calprotectin and lactoferrin levels 
were 1707.6µg/g and 165.8µg/g, these normalised at first month post-
operatively. Both his faecal calprotectin and lactoferrin climbed to 78.9µg/g 
and 22.1µg/g at 9th month as he relapsed and was started on infliximab. And 
at 12 months his markers normalised. 
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Table 4.3 – Individual patient profile for the 5 complicated post-operative 
recovery patients. 
 
 
 
 Chapter 4 – Longitudinal Study Results 
121 
 
0 Pre 1w 2 3 4w 2m 3 4 5 6 9 12m
1
100
10000
A
B
C
D
E
Time
Fa
ec
al
 
Ca
lp
ro
te
ct
in
m
ic
ro
gr
am
/g
ra
m
(lo
g 
ba
se
 
10
)
50
  
Figure 4.3 - Faecal calprotectin concentration (individual values) 
preoperatively and at post operative follow up for the 5 patients with 
complicated post-operative recovery. 
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Figure 4.3a - Faecal calprotectin concentration (median values) 
preoperatively and at post operative follow up for the 5 patients with 
complicated post-operative recovery. 
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Figure 4.4 - Faecal lactoferrin concentration (individual values) 
preoperatively and at post-operative follow up for the 5 patients with 
complicated post operative recovery. 
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Figure 4.4a - Faecal lactoferrin concentration (median value) preoperatively 
and at post-operative follow up for the 5 patients with complicated post 
operative recovery. 
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5.1 Discussion on faecal markers: 
This study (Cross-sectional and Longitudinal) has shown that the 
quantitative measurement of faecal calprotectin and faecal lactoferrin offer a 
valuable non-invasive method of assessing symptomatic post-operative 
patients with Crohn’s disease. Both faecal calprotectin and faecal lactoferrin 
tests have been demonstrated as reproducible and correlated well with one 
another. After uncomplicated ileocaecal resection for Crohn’s disease, both 
faecal calprotectin and faecal lactoferrin normalised in 2 months. Both 
remained within normal range (faecal calprotectin < 50µg/g and faecal 
lactoferrin < 7.25µg/g) unless there was a recurrence of gastrointestinal 
inflammation.  
 
A previous report by Roseth et al [150] demonstrated that normalization of 
faecal calprotectin was associated not just with clinical remission but 
mucosal healing. Findings from this study (figure 4.1a and 4.2a), could 
suggest that in symptomatic post-operative patients, a single faecal 
calprotectin or faecal lactoferrin measurement at 2 months or more after 
ileocaecal resection could identify genuine disease recurrence and help to 
target immunosuppressant therapy. In patients who have had ileocaecal 
resection where the levels of faecal calprotectin or faecal lactoferrin 
remained at low levels, but have symptoms, are unlikely to have mucosal 
inflammation. The symptoms in this patient group may be due to altered 
anatomy, bile salt malabsorption or functional bowel disease. In this group 
of patients conservative management using anti-motility drugs such as 
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loperamide and cholestryamine should be considered. In contrast 
symptomatic patients, who had ileocaecal resection with high levels of 
faecal calprotectin or faecal lactoferrin, could have higher degree of 
mucosal inflammation. This group of symptomatic patients may benefit from 
agents such as thiopurines or anti-TNF- alpha antibodies. From this study, it 
has not been demonstrated that faecal calprotectin test is superior to faecal 
lactoferrin and neither can be used reliably as a single measurement to 
quantify gastrointestinal inflammation in post-operative Crohn’s disease and 
vice-versa.     
 
Among the various serological markers such as C-reactive protein, platelet 
count stands out for assessment of intestinal inflammation and correlation 
with symptoms and disease activity index [166]. These markers have low 
sensitivity and specificity for gastrointestinal inflammation and poorly 
correlate with symptoms and disease activity indexes. In this study both 
faecal calprotectin and faecal lactoferrin correlated more strongly with 
disease symptoms scoring according to HBI than CRP and platelet count 
(table 3.2). These faecal markers may therefore give more accurate 
reflection of gastrointestinal inflammation than the more commonly used 
serological markers. Similar findings to our study were seen in a study from 
Langhost et al [144]; they showed faecal calprotectin and faecal lactoferrin 
to be superior to C-reactive protein in overall assessment of gastrointestinal 
inflammation and correlation with clinical disease score. 
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Sipponen et al [172] and colleagues concluded that for evaluation of 
Crohn’s disease activity based on endoscopic findings, faecal calprotectin 
and faecal lactoferrin are more sensitive markers. Surprisingly in our study, 
no significant difference was noticeable in faecal calprotectin or faecal 
lactoferrin concentration between patients with endoscopic evidence of 
gastrointestinal inflammation and those with normal endoscopic findings.  
 
A study by D’Inca et al [130] was conducted to evaluate the efficacy of 
faecal calprotectin and faecal lactoferrin in detecting organic disease as 
assessed by colonoscopy. This study involved 144 patients undergoing 
colonoscopy for lower gastrointestinal symptoms or inflammatory bowel 
disease activity or surveillance for dysplasia. They concluded a significant 
correlation between colonic inflammation at endoscopy and faecal 
calprotectin, and between histological inflammation and faecal lactoferrin 
but not vice versa. In our study using faecal calprotectin and faecal 
lactoferrin as markers in post-operative recurrence in Crohn’s disease 
surprisingly, no significant difference was apparent in faecal calprotectin and 
faecal lactoferrin levels between patients with endoscopic evidence of 
inflammation and those with normal endoscopic finding [1]. D’Inca et al 
recommended adjusting the cut-off values of both faecal calprotectin and 
faecal lactoferrin in the IBD group. However it should be noted that D’Inca 
and colleagues used a quantitative assay for faecal calprotectin but only a 
qualitative assay for faecal lactoferrin in contrast to our study where both 
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quantitative assay were used for both faecal calprotectin and faecal 
lactoferrin.  
 
Previous research in patients with Ulcerative Colitis has suggested that 
faecal calprotectin correlates with the degree of inflammation rather than 
disease extent and the levels of faecal calprotectin are significantly higher in 
active small bowel Crohn’s disease [149]. Therefore it may be that patients 
with high faecal calprotectin or faecal lactoferrin levels but normal 
endoscopy have active small bowel disease beyond the reach of 
colonoscope. It is also worth noting that the time between colonoscopy and 
interview in the present study was up to 4 weeks. The longitudinal data 
result demonstrated that there can be significant variation in faecal 
calprotectin and faecal lactoferrin levels within this time; hence when 
comparing faecal calprotectin and faecal lactoferrin levels with endoscopic 
finding, the interval between the two is a limitation.  
 
Among various serological markers available like ESR, CRP, ANCA, platelet 
count and ASCA only CRP stands out in literature for assessing 
gastrointestinal inflammation and correlates with symptom and disease 
activity index [166]. However, CRP has low sensitivity and specificity and 
correlates poorly with gastrointestinal inflammation and disease activity 
index in IBD compared to faecal calprotectin and lactoferrin [4]. The current 
study has also demonstrated that both faecal calprotectin and lactoferrin 
correlate more strongly than CRP, WCC or platelet count with disease 
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symptoms scoring according to Harvey Bradshaw Activity Index [1], and 
may therefore give a more accurate reflection of gastrointestinal 
inflammation than these more commonly used serological markers. 
In patients who had a complicated (intra-abdominal collection, wound 
infection, recurrence of disease) post-operative recovery, their both faecal 
calprotectin and lactoferrin increased above normal and normalized again 
after they responded to therapy. Burdeus and co-workers have 
demonstrated that in a paediatric population with Crohn’s disease faecal 
lactoferrin could be useful in monitoring response to infliximab therapy when 
compared with the paediatric CDAI [183]. Kolho and colleagues[151]  have 
shown that, although faecal calprotectin decreases in line with clinical 
response in patients with active IBD treated with corticosteroids, it does not 
always normalize. A likely explanation is the fact that corticosteroids do not 
induce the full resolution of mucosal inflammation [52] which could be 
achieved by other therapeutic means such as azathioprine or infliximab 
therapy [106, 107, 190]. 
 
The most novel finding of this study was the association between faecal 
calprotectin and faecal lactoferrin concentrations and long-term active and 
inactive disease in post-operative patients. The cross-sectional study 
showed a high degree of correlation between clinical disease activity and 
high and low levels of intestinal inflammation defined by a faecal 
calprotectin or faecal lactoferrin more or less than twice the upper limit of 
normal. In patients with no clinical disease activity (HBI score of less than 
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3), most patients had low levels of both faecal calprotectin and lactoferrin 
(less than twice the upper limit of normal), and therefore low levels of 
intestinal inflammation. Those with very active disease (HBI score of 6 or 
more) generally had high levels of gut inflammation (faecal calprotectin and 
faecal lactoferrin both over twice the ULN- table 3.3). However, in the 
heterogeneous group of patients (those with mild or moderate symptoms of 
disease activity {HBI score 4-5} formed a far more diverse group. This is 
important to recognize, as often these are the most challenging patients in 
which to distinguish inactive from active disease. The finding of an almost 
equal split between patients with high and those with low levels of gut 
inflammation within a similar spectrum of clinical disease suggests that a 
single measurement of faecal calprotectin and faecal lactoferrin could allow 
treatment targeting between immunosuppression for those with high 
concentrations of faecal granulocyte degradation products and symptomatic 
treatment for those with low concentrations. 
 
This evidence favouring the routine use of faecal granulocyte markers in 
post-operative Crohn’s disease is supported by the work of Orlando and co-
workers [158]. They investigated the role of faecal calprotectin 
measurement, ultrasound (both performed at third month after surgery) and 
colonoscopy (performed at one year after surgery) predicting disease 
recurrence in patients with asymptomatic Crohn’s disease within a year of 
resection, finding that a cut-off value of faecal calprotectin at 200 µg/l gave a 
sensitivity of 63% and specificity of 75%. They therefore recommended that 
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this value could be used as a tool to decide which patients should have 
colonoscopy after surgery.  
 
Another cross-sectional study was conducted in post-operative Crohn’s 
disease setting by Scarpa and colleagues [155] in a small cohort to assess 
faecal calprotectin and faecal lactoferrin concentrations randomly at a 
median follow up of 40.5 months after ileocolonic resection surgery. Using 
the Crohn’s disease activity index (CDAI), they too demonstrated that some 
patients have a high faecal calprotectin and lactoferrin concentrations after 
surgery even in clinical remission. However, because their cohort was 
smaller than the present study, they could not stratify clinical disease 
activity, nor compare faecal calprotectin and faecal lactoferrin 
measurements. Furthermore, they did not have a cohort of patients with 
serial measurements of faecal calprotectin or lactoferrin from the time of 
surgery.  
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5.2 Conclusions: 
This study has shown that quantitative measurements of faecal calprotectin 
and faecal lactoferrin offers a valuable, non-invasive method of assessing 
symptomatic postoperative patients with Crohn’s disease. Both this tests 
have been demonstrated as reproducible and correlated well with one 
another. Compared to other measurements of inflammatory activity both 
these markers are better in identifying clinical disease activity. After 
uncomplicated ileocaecal resection for Crohn’s disease, both markers 
normalized by two months [1]. Faecal calprotectin and lactoferrin 
measurement can be recommended for routine use in post-operative 
patients to help target immunosuppressant therapy. With this study using 
these two non-invasive markers, a proposed algorithm for monitoring & 
treatment after ileocaecal resection for Crohn’s disease is shown below 
(figure 4.5). 
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Post-operative Crohn’s disease 
No Standard algorithm available              Some get Colonoscopy 6-12 mnts 
                                                                 Others - No Colonoscopy  
Resection of all macroscopic Crohn’s disease 
(Right Hemicolectomy +/- Ileal resection) 
 
Post-operative recovery 
 
Assessment of risk at 0-4 months 
 
Faecal calprotectin/faecal lactoferrin levels at 2-4 months post surgery 
 
Low Levels of markers +                                 High levels of markers + 
Low & intermediate risk                                   High risk 
1) No smoking                                                  1) Currently smoking 
2) First surgery                                                 2) Repeated surgery 
3) No perforating disease                                 3) Perforating disease 
 
 
Continue review                                     Escalate treatment +/- Colonoscopy 
 
Figure 4.5 – Proposed algorithm for monitoring & treatment for Crohn’s 
disease after Ileocaecal resection. 
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5.3 Limitation of the study: 
The limitation of the study in this group of post-operative patients is the lack 
of a ‘gold standard’ test of disease recurrence. A colonoscopy for each 
patient would have been ideal, but still incomplete assessment of the 
Crohn’s disease. The degree of testing would not be in the patient’s interest 
as it is too invasive. It is therefore hard to validate the use of any test fully. 
There is also a degree of subjectivity and bias associated with the use of 
clinical indices such as the Crohn’s Disease Activity Index and Harvey 
Bradshaw Activity Index, although clinical indices do reflect individual well-
being, which in clinical practice is used to guide management. 13 patients in 
the longitudinal study are smaller than ideal and shorter follow up of 1 year. 
This study was designed to be achievable in the time frame and within 
budget available as well as acceptable to patients by virtue of not involving 
any invasive tests. 
 
5.4 Future prospects: 
In summary, the results from this study are encouraging for the use of faecal 
granulocyte degradation product markers in the post-operative surveillance 
of Crohn’s disease patients and should stimulate larger randomized 
prospective trials evaluating if disease monitoring by faecal markers alters 
clinical outcomes in the long term follow up.  
 
Future trials are desirable to investigate targeted azathioprine or anti-TNF 
therapy in those with high faecal calprotectin or faecal lactoferrin levels, and 
  Chapter 5 - Discussion 
134 
 
withdrawing or reducing immunosuppressant therapy in those with low 
faecal calprotectin or faecal lactoferrin levels. 
 
Already research and development and research ethics committee have 
approved a pre-pilot longitudinal study (to be conducted at Newcastle upon 
Tyne Hospitals NHS foundation trust and Newcastle University) to monitor 
fluctuations and trends in faecal calprotectin and lactoferrin, in a cohort of 
patients treated with anti-TNF antibody therapy over a 6  month time period. 
The hypothesis of future study is that prior to a symptomatic flare up of 
Crohn’s disease, there will be a period of time where a rise in faecal 
biomarkers from baseline can be observed without patient’s experiencing a 
clinical change. This period of subclinical disease activity may be an ideal 
target for therapeutic intervention.  There is a large national study (TOPPIC) 
from Edinburgh in post-operative setting on Crohn’s disease is underway 
using faecal calprotectin and faecal lactoferrin. This study involves collecting 
290 patients prospectively for 2-3 years and help target immunosuppression 
therapy. This will add additional information about post-operative Crohn’s 
disease apart from my thesis and expanded data will give further evidence 
for change of practice.      
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2) Patient consent form: Cross-sectional study: 
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3) Patient information sheet: Longitudinal study: 
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4) Patient consent from: Longitudinal study: 
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